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 Abstract 
 
Introduction: The incidence of breast cancer in Eastern Asia is approximately 3-
times lower than in western countries, and nutrition seems to play an important role. 
The traditional East Asian diet is rich in soy, which is the main source of the 
isoflavones (ISO) genistein (GEN), daidzein (DAI), and glycitein (GLY). Some 
evidence suggests that ISO intake must be high during certain windows of 
development to exert anti-cancerogenic action. The aim of the present thesis was to 
investigate the effects of soy ISO exposure in different periods of life on the 
estrogen sensitivity of the mammary gland and homeostasis of the small intestine in 
female rats. 
Methods: In a first experiment, animals were exposed to an ISO-free (IDD), an ISO-
rich (IRD; 248 µg GEN, 213 µg DAI, 59 µg GLY per g diet) or an IDD diet 
supplemented with GEN (GRD; 700 µg GEN per g diet), throughout their whole 
lifetime. At the age of 50 (PND 50) and 80 days (PND 80) proliferative activity was 
analysed in the mammary gland and compared to ISO serum concentrations. 
Additionally, the tissue homeostasis of the small intestine was determined. In order 
to analyze estrogen sensitivity of the mammary gland IDD, IRD and GRD rats (PND 
80) were ovariectomized and treated either with vehicle (OVX), estradiol (E2; 7.8 
µg/g BW/day), or GEN (19.6 mg/kg BW/day). In a second experiment, two group of 
rats were lifelong exposed to either an IDD or to an ISO-containing diet (ISD; 147 µg 
GEN, 114 µg DAI, 36 µg GLY per g diet). A third group received the ISD only from 
shortly before the onset of puberty (PND 30) up to the end of puberty (PND 60; 
pISD). Animals were treated with vehicle (OVX), E2 (4 µg/g BW/day) or GEN (10 
mg/kg BW/day). As in the first experiment, the responsiveness of the mammary 
gland was analysed. 
Results: At PND 50, PCNA expression showed an increase in the mammary gland 
of both IRD and GRD animals compared to the IDD group. In the small intestine an 
increased PCNA and PS2-expression could be measured. Differences in the 
expression of PCNA in the mammary gland could neither be detected in intact rats 
at PND 80, nor at PND 97 for OVX and GEN treated rats, whereas treatment with E2 
resulted in a significant lower proliferative (PCNA expression) and estrogenic (PR 
and ERα expression) response of the mammary gland in the IRD and GRD group 
compared to the IDD animals. In contrast, the expression of estrogen receptor beta 
(ERβ) and PS2 was significantly higher in IRD and GRD fed animals compared to 
the IDD group. In the second experiment, the proliferative activity in the mammary 
gland was not affected by IDD and ISD, while a significant increase could be 
detected for pISD animals at day 50. The analysis of Ki-67 and PCNA mRNA 
expression showed that the proliferative response to E2 was significantly reduced in 
the pISD and ISD group compared to IDD. The induction of PR mRNA expression 
was significantly increased in both IDD and pISD animals compared to ISD.  
Conclusions: The data of the present studies provide evidence that lifelong 
exposure to soy ISO reduces the sensitivity of the mammary gland towards E2 and 
seems to improve protective mechanism of the small intestine. Additionally, it could 
be shown that ISO exposure starting first shortly pre-pubertal appears sufficient to 
reduce the proliferative response of the mammary gland towards estrogens. 
 
  
 Kurzfassung 
 
Einleitung: Die Inzidenz von Brustkrebs ist in Ostasien um ein 3-faches niedriger 
als in westlichen Ländern und die Ernährung scheint hierbei eine bedeutende Rolle 
zu spielen. Die traditionelle ostasiatische Ernährung ist reich an Soja, welches die 
Hauptquelle für die Isoflavone (ISO) Genistein (GEN), Daidzein (DAI) und Glycitein 
(GLY) ist. Einige Studien deuten an, dass die ISO-Aufnahme zu bestimmten 
Entwicklungsstadien erfolgen muss, damit antikanzerogene Effekte erzielt werden 
können. Ziel der vorliegenden Dissertation war es zu untersuchen, wie sich eine 
ISO-reiche Ernährung zu verschiedenen Zeitpunkten des Lebens auf die 
Estrogensensitivität der Brustdrüse und die Gewebehomöostase des Dünndarms 
weiblicher Ratten ausübt. 
Methoden: In einem ersten Experiment erhielten die Tiere lebenslang entweder 
eine ISO-freie Diät (IDD), eine ISO-reiche Diät (IRD; 248 µg GEN, 213 µg DAI, 59 
µg GLY pro g Futter) oder eine IDD supplementiert mit Genistein (GRD; 700 µg 
GEN pro g Futter). Im Alter von 50 (PND 50) und 80 Tagen (PND 80) wurde die 
proliferative Aktivität in der Brustdrüse mit den ISO-Konzentrationen im Serum 
verglichen. Zusätzlich wurde die Gewebehomöostase im Dünndarm bestimmt. Um 
die estrogene Sensitivität der Brustdrüse zu analysieren wurden IDD, IRD und GRD 
Ratten ovariektomiert und entweder mit dem Lösungsmittel (OVX), Estradiol (E2; 7.8 
µg/g KG/Tag) oder GEN (19.6 mg/kg KG/Tag) behandelt. In einem zweiten 
Experiment erhielten zwei Tiergruppen entweder eine IDD oder eine ISO-haltige 
Diät (ISD; 147 µg GEN, 114 µg DAI, 36 µg GLY pro g Futter). Eine dritte 
Ernährungsgruppe wurde erst ab kurz vor Beginn der Pubertät (PND 30) bis zum 
Ende der Pubertät (PND 60) mit einer ISD gefüttert (pISD). Die Tiere wurden 
entweder mit dem Lösungsmittel (OVX), E2 (4 µg/g KG/Tag) oder GEN (10 mg/kg 
KG/Tag) behandelt. Auch in diesem Experiment wurde die Responsivität der 
Brustdrüse untersucht. 
Ergebnisse: An PND 50 war die PCNA Expression in der Brustdrüse von IRD und 
GRD Tieren, verglichen mit der IDD-Gruppe, erhöht. Im Dünndarm resultierten IRD 
und GRD in erhöhter Proliferation und PS2-Expression. An PND 80 waren keine 
Unterschiede in der PCNA Expression in der Brustdrüse von intakten, an PND 97 in 
OVX und GEN Tieren zu beobachten, wohingegen eine Behandlung mit E2 in einer 
signifikant niedrigeren proliferativen (PCNA Expression) und estrogenen (PR und 
ERα Expression) Responsivität der Brustdrüse in der IRD und GRD Gruppe 
verglichen mit der IDD resultierte. Im Gegensatz dazu war die Expression des 
Estrogenrezeptor Beta (ERβ) und von PS2 in Tieren, die eine IRD oder GRD 
erhielten signifikant höher als in der IDD-Gruppe. Im zweiten Experiment war die 
proliferative Aktivität an PND 50 durch IDD und ISD nicht beeinflusst, wobei ein 
signifikanter Anstieg bei pISD-Tieren beobachtet wurde. Die Analyse von Ki-67 und 
PCNA mRNA zeigte, dass die proliferative Antwort auf E2 in der pISD und ISD-
Gruppe, verglichen mit der IDD, signifikant reduziert war. Die Induktion der PR 
mRNA Expression war sowohl in IDD als auch in pISD-Tieren signifikant erhöht.  
Schlussfolgerungen: Die Ergebnisse der vorliegenden Studien belegen, dass eine 
lebenslange Exposition gegenüber ISO die Sensitivität der Brustdrüse gegenüber E2 
reduziert und wahrscheinlich den Schutzmechanismus des Dünndarms verbessert. 
Zusätzlich wurde gezeigt, dass eine ISO-reiche Ernährung, die erst kurz vor 
Einsetzen der Pubertät beginnt, ausreichend scheint, um in der Brustdrüse die 
proliferative Reaktion auf Estrogene zu reduzieren. 
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CHAPTER ONE 
General Introduction 
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The most common hormone dependent cancer occurring to women is breast 
cancer, with increasing incidence in postmenopausal women. The second most 
common is bowel cancer. Although bowel cancer has not been regarded as being 
hormone-dependent for a long time, the observation that 2-times more men than 
premenopausal women are suffering from this disease indicates a protective role of 
female sex hormones. Underlined is this assumption by the observation that bowel 
cancer risk for women increases after menopause (Calle et al., 1995; Messina & 
Bennink, 1998; Di Leo et al., 2001). Furthermore, treatment with estrogens in the 
context of hormone replacement therapy decreases the risk of bowel cancer in 
postmenopausal women, whereas breast cancer risk increases at the same time 
(Chen et al., 1998; Nelson et al., 2002; Beral, 2003; Chlebowski et al., 2004; Wada-
Hiraike et al., 2006; Chlebowski et al., 2009).  
That the incidence of these hormone-dependent diseases is much lower in Eastern 
Asia compared to Europe or the United States has been characterized many years 
ago (Adlercreutz et al., 1992; Knight & Eden, 1996; Setchell & Cassidy, 1999; 
Messina & Wood, 2008). Questions arose about the factors reducing the cancer risk 
in the Asian population and migration studies were performed to analyse whether 
genetic differences were responsible for these effects. In respect to breast cancer it 
has been shown that Asian women which migrated to the United States lost the 
cancer protection if adapting the American diet (Ziegler et al., 1993; Stanford et al., 
1995). Further studies showed that the cancer protection persists if the migration 
occurred after puberty (Shu et al., 2001; Wu et al., 2002). These observations led to 
the assumption that nutrition in early life plays a key role in the prevention of 
hormone dependent cancers. 
The traditional East Asian diet is rich in soy-based food products. Soy is the main 
source of isoflavones (ISO; 10–30 mg ISO/g protein) and contains, in descending 
concentrations (10:8:1), the ISO genistein (GEN), daidzein (DAI), and glycitein 
(GLY) (Walz, 1931; Horn-Ross et al., 2000). ISO belong to the class of 
phytoestrogens, and because of their structural similarity to endogenous estrogens, 
ISO are able to bind to both estrogen receptors and subsequent initiate estrogen 
action. Although the estrogenic activity of ISO is 100 to 10,000-times lower 
compared to the endogenous estrogen 17β-estradiol (E2), the plasma 
concentrations of biological active ISO can reach 100 to 1,000-times of the level of 
free estrogens. This is due to the lower binding affinity of ISO to sexual-hormone-
binding globulines (Limer & Speirs, 2004). 
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Soy intake in the Asian population consuming a traditional diet range between 6 and 
11 g soy protein per day, resulting in 25–50 mg ISO (calculated as aglykone). About 
10 % of the Asians reach a high intake of 25 g soy protein per day (100 mg ISO as 
aglykone equivalent). In contrast, consumption of less than 1 mg soy protein per day 
is common in Europe (Adlercreutz, 1998; Setchell & Cassidy, 1999; Munro et al., 
2003; Sirtori et al., 2005). Beside differences in the daily ISO uptake, the exposure 
pattern differs between both populations. In Asia, relative large amounts of soy 
products are consumed throughout life, which result in an ISO exposure already in 
utero, because the fetus is exposed to the same ISO levels as found in the maternal 
circulation during pregnancy (Doerge et al., 2006). On the contrary, most European 
people do not consume large amounts of soy products in their life. In the last years, 
soy-based supplements are advertised as an effective and side-effect-free 
alternative to hormone replacement therapy in postmenopausal women. The users 
of these supplements are exposed to high doses of ISO in a purified form for the first 
time in their life in a late adult stage. The dosage of the soy-based dietary 
supplements varies between 20 and 80 mg ISO/day, but sometimes doses up to 
150 mg ISO/day are recommended (Wei et al., 2012; Ferrari, 2009).  
Although no harmful effects of soy ISO has been described so far if the consumption 
occurred as a regular part of the diet, the effects of isolated and/or high-dosed ISO 
consumption are discussed controversial. Health beneficial declarations of soy-
based dietary supplements usually refer to Asian populations and their consumption 
of soy, whereas epidemiologic studies in European populations have shown that the 
efficiency of ISO to treat hormone dependent diseases is questionable (Tomar & 
Shiao, 2008; Wu et al., 2008).  
Cell culture and animal studies even indicate that ISO increase the risk of breast 
cancer, especially estrogen-dependent carcinomas, because of their estrogenic 
activity. Furthermore, it has been shown that the stimulating effects of GEN on 
tumor growth depend on ISO concentration and estrogen status (Wang et al., 1996; 
Ju et al., 2006). Also, results of animal studies have indicated that ISO may either 
prevent or promote carcinogenesis, depending partly on the developmental stage of 
the animal and mostly on factors that have not yet been understood. Additionally, 
animal studies indicate that ISO exposure during pre-puberty provide protection 
against breast cancer later in life. In rats, pre-pubertal exposure to GEN until 
postnatal day 20 resulted in altered morphology of mammary glands, reduced 
numbers of terminal end buds, increased lobular differentiation, and reduced breast 
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cancer incidence when tumor growth was subsequently induced by carcinogen 
treatment (Warri et al., 2008).  
Regarding the intestine, several in vitro and in vivo studies showed that GEN and E2 
are able to influence intestinal homeostasis, whereas the results of these studies 
remain conflicting (Booth et al., 1999a; Booth et al., 1999b; Chen et al., 2005; Javid 
et al., 2005; Weige et al., 2009). It is assumed that GEN and E2 exert their effects in 
the intestine via activating the ERβ. It has been shown that over-expression of ERβ 
resulted in a reduction of proliferation in human cancer cells, suggesting that some 
key regulators of the cell cycle are modulated by the ERβ (Martineti et al., 2005). 
Altogether, GEN as a ligand of the ERβ may serve as potential regulators of 
intestinal tissue, whereas the underlying mechanisms are still unclear. 
Given the challenge to transfer data from animal models to the human situation, a 
number of clinical studies have investigated the effects of ISO exposure on human 
breast and intestine so far, but the results of these studies are conflicting and did not 
provide clear evidence with respect to health risks or benefits of ISO uptake 
(Nagata, 2010; Adlercreutz & Mazur, 1997; Setchell & Cassidy, 1999; Messina & 
Loprinzi, 2001; Adams et al., 2005; Duffy et al., 2007; Mense et al., 2008; Yang et 
al., 2009). This may be due to limitations of the study designs, such as the lack of 
suitable control groups, variations in or even unknown composition of the consumed 
products or limited number of readouts. It is questionable whether further clinical 
and epidemiologic studies alone will provide sufficient data to answer all the 
questions regarding the effect of ISO exposure on risk of breast and bowel cancer. 
To improve the knowledge about the apparently contradictory effects of ISO the 
underlying molecular mechanisms have to be investigated. 
To our knowledge, no data exists regarding the impact of lifelong exposure to ISO 
on estrogen sensitivity of the mammary gland and on tissue homeostasis of the 
small intestine of females. The present thesis should make an important contribution 
to understand molecular mechanisms that are affected by ISO and whether intake of 
ISO may be protective or adverse with respect to the risk of developing breast and 
bowel cancer. 
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OBJECTIVES OF THE THESIS 
 
The main research objective of the present thesis is to improve knowledge about the 
beneficial or adverse effects of ISO on the mammary gland and the small intestine. 
In order to make a contribution to the elucidation of involved molecular mechanisms, 
the major aim of this thesis was to investigate effects of lifelong ISO exposure on the 
estrogen sensitivity of the mammary gland and the small intestine of female rats. For 
this purpose, the thesis addresses the following three key research questions: 
 
• CHAPTER TWO: 
Is the estrogen sensitivity of the mammary gland influenced by in utero and 
postnatal exposure to soy ISO or to solely GEN via diet? 
 
• CHAPTER THREE: 
In which way is the tissue homeostasis of the small intestine of female rats 
modulated by lifelong exposure to ISO or to GEN? 
 
• CHAPTER FOUR: 
How important is the time of ISO exposure for their protective effects on the 
mammary gland? 
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CHAPTER TWO 
 
 
In utero and postnatal exposure to isoflavones results in a reduced 
responsivity of the mammary gland towards estradiol* 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*published in Mol Nutr Food Res 2012; 56(3):399-409.  
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Abstract: 
Scope: Exposure scenarios during different stages of development of an organism 
are discussed to trigger adverse and beneficial effects of isoflavones (ISO). The aim 
of this study was to investigate how in utero and postnatal ISO exposure modulates 
the estrogen sensitivity of the mammary gland and to identify underlying molecular 
mechanisms.  
Methods and results: Therefore rats were exposed to either ISO-free (IDD), ISO-
rich (IRD) or genistein rich diet (GRD), up to young adulthood. Proliferative activity 
(PCNA expression) in the mammary gland at different ages and the estrogen 
sensitivity of the mammary gland to estradiol (E2) or genistein (GEN) in adult 
ovariectomized animals was determined and compared to the different treatments. 
Treatment with E2 resulted in a significant lower proliferative and estrogenic 
response of the mammary gland in IRD and GRD compared to IDD. This correlates 
to a change in the gene expression pattern and a decrease in the ratio of estrogen 
receptor alpha (ERα) beta (ERβ).  
Conclusion: Our results provide evidence that in utero and postnatal exposure to a 
diet rich in ISO but also to GEN reduces the sensitivity of the mammary gland 
towards estrogens and support the hypothesis that in utero and postnatal ISO 
exposure reduces the risk to develop breast cancer. 
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Introduction: 
The incidence of breast cancer in Eastern Asia is approximately 3-time lower than in 
western countries (Mense et al., 2008). It has been hypothesized that nutrition plays 
an important role in the prevention of hormone dependent breast cancer 
(Adlercreutz & Mazur, 1997). The traditional East Asian diet includes soy, which is 
the main source of isoflavones (ISO), belonging to the class of phytoestrogens. Soy 
ISO show a polyphenolic non-steroidal structure and their hydroxyl groups at C-7 of 
the A-ring and C-4´of the B-Ring of the ISO skeleton exhibit a distance similar to 
those of the endogenous estrogens. Because of this similarity, ISO exert the ability 
to bind to both estrogen receptor subtypes (ER), with a higher affinity to the ERβ, 
and subsequently initiate estrogen-dependent transcription (Newbold et al., 2001).  
The estrogenic potency of ISO is much lower compared to estrogens, but the 
circulating concentration of ISO can reach much higher levels after ingestion of soy 
food or soy-derived dietary supplements. The daily uptake of soy ISO in the various 
Asian countries range around 20–50 mg, resulting in ISO plasma concentrations of 
870 nM, while the Western population ingests 1 mg ISO per day (Setchell & 
Lydeking-Olsen, 2003), which lead to plasma concentrations of ISO as low as 10 nM 
(Adlercreutz et al., 1993). Intake of ISO via supplements normally range between 20 
and 80 mg/day, resulting in ISO plasma concentrations in the range of 1–3 µM. 
Whether effects of ISO are beneficial or not is controversially discussed. A 
protective effect of ISO towards bone health is described in animal studies (Branca, 
2003; Hertrampf et al., 2009a; Hertrampf et al., 2009b), although questionable for 
the human situation as neither a randomized double blind placebo controlled study 
nor a recent meta-analysis were able to provide evidence (Brink et al., 2008; Liu et 
al., 2009). A benefit of ISO on hot flushes is also controversially discussed (Ferrari, 
2009; Jacobs et al., 2009).  
The same controversy exists regarding the outcome of ISO intake in respect to 
breast cancer. For example in an animal model which mimics key aspects of 
postmenopausal conditions by inoculating MCF-7 breast cancer cells into 
immunodeficient nude mice an increase in breast tumor growth was detected after 
treatment with GEN (Ju et al., 2006). In vitro for MCF-7 breast cancer cells a 
biphasic effect on cell growth dependent on concentration could be observed in 
response to GEN (Wang et al., 1996). The National Toxicology Program (NTP) 
conducted a two years multigenerational GEN study in Sprague Dawley rats, which 
was recently reviewed by Doerge (Doerge, 2011). The key results relevant to this 
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study were that depending on the study arm a trend for increased incidences of 
mammary adenoma and adenocarcinoma could be observed in the 5 ppm and 100 
ppm GEN feeding group, which although the absolute numbers were relatively low, 
reached statistical significance in the 500 ppm feeding group (Doerge, 2011; 2008a; 
2008b). However, there is also evidence that in utero and postnatal or neonatal ISO 
or GEN exposure may protect against breast cancer (Whitsett & Lamartiniere, 2006; 
Lee et al., 2009). In addition, soy ISO intake was found to be inversely correlated to 
mortality and recurrence from breast cancer. 
To understand these controversial results it is important to have a closer look 
towards the risk factors involved in the development of breast cancer. Risk factors 
for breast cancer are early onset of menarche, late onset of menopause and high 
amounts of free circulating E2 in the serum of post-menopausal women (Toniolo et 
al., 1995; Lu et al., 1996; Hulka & Moorman, 2001). ISO has the ability to increase 
the amount of sex hormone binding globuline, which results in a reduction of free, 
bioavailable circulating estrogens (Adlercreutz et al., 1987). This conforms to the 
fact that compared to Western women the free serum-estradiol levels of Asian 
women are 40 % lower (Peeters et al., 2003). Beside the concentration of circulating 
estrogens also the estrogen sensitivity of the non-malignant breast tissue may be 
altered by ISO. There is evidence that ISO may influence the development of the 
mammary gland, starting already in utero. A rudimentary gland is present at birth, 
and during puberty, hormone-dependent development of the mammary gland occurs 
(Lanigan et al., 2007). Various studies suggest a protective effect of ISO if the 
ingestion starts before onset of puberty (Limer & Speirs, 2004; Browning et al., 
2005). Furthermore, it has been shown that pre-pubertal exposure to GEN alters the 
development of the mammary gland (Warri et al., 2008). Hence, it seems 
reasonable that the exposure to ISO has to begin before pubertal breast 
development starts in order to exert protective effects as recently proposed 
(Messina & Hilakivi-Clarke, 2009). 
Information whether the ISO exposure during puberty and in further developmental 
stages alters the sensitivity of breast tissue towards estrogens or ISO in 
postmenopausal woman is still limited. However, as recently reviewed the degree of 
maturation of terminal end buds appears to play a key role (Jenkins et al., 2012). 
While studies investigating environmental endocrine disrupters, e.g. bisphenol A, 
suggest that early embryonic exposure significantly impacts on tissue 
(patho)physiology and hormone responsiveness later in life by delaying maturation 
(Betancourt et al., 2010), the tumor preventive effect of neonatally administered 
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GEN appears to occur through advanced differentiation of these glandular structures 
which is paralleled by alterations in cell proliferation and apoptosis as well as up-
regulation of tumor-suppressor genes (reviewed in (Jenkins et al., 2012; Whitsett & 
Lamartiniere, 2006)). Taking into consideration that manufacturers advertise dietary 
soy supplements as an effective alternative to conventional HRT without adverse 
side effects, the understanding of the consequences of an early ISO exposure 
seems of fundamental importance. 
The aim of this study was to investigate the effect of in utero and postnatal ISO 
exposure on estrogen sensitivity of the mammary gland in adult intact and 
ovariectomized female rats. The animals were fed diets containing different amounts 
of ISO. The ISO exposure was initiated in utero, maintained during neonatal, and 
pre-pubertal stages of development and adhered until adulthood. It is well known 
that an increased cell proliferation rate is associated with a high risk of developing 
breast cancer. For that reason the proliferation in the mammary gland was 
determined as a biological endpoint for estrogen sensitivity. In addition, the 
expression of the progesterone receptor (PR), the estrogen receptor α (ERα) and 
estrogen receptor β (ERβ) and PS2 was investigated.  
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Materials and Methods 
Experimental animals and study design 
All animal handling and experimental conditions were carried out according to the 
“Institutional Animal Care and Use Committee guidelines”, regulated by the German 
federal law for animal welfare (Permission Number 50.203.2-K15). 
Wistar rats were obtained from Janvier (Le Genest St Isle, France) and kept under 
controlled conditions of temperature (20°C ± 1), relative humidity (50–80 %) and 
illumination (12 h dark, 12 h light). Female rats were mated and the dams (7 in each 
dietary group) were fed one of the three diets during pregnancy and nursing. After 
weaning the female offspring of each nutrition group (30 each group) was randomly 
assigned to five treatment groups (6 each group), to make sure that pups from 
different mothers generate a group. These rats had ad libitum access to the 
appropriate diet and water. 
 
Fig. 1: Timeline and experimental setting of the study depicting modes of isoflavone exposure (in 
utero, lactational, and dietary) and points of time for analysis. A In intact PND 50 and PND 80 the ISO 
content were measured in the serum and the proliferation were determined in the mammary gland. B 
After ovariectomie on PND 80, animals were treated with E2, GEN, or the vehicle from PND 94 up to 
PND 97 and were sacrified afterwards. In these animals the proliferation and the estrogenic response 
of the mammary gland were determined. 
 
In utero  
exposure 
lactational 
exposure 
Dietary exposure 
Birth Ablactation Postpuberty Ovariectomie 
PND 1 PND 21 PND 80 PND 97 
Section 
Treat-
ment 
Start 
PND 94 
A 
B 
In utero 
exposure 
lactational 
exposure 
Dietary exposure 
Birth Ablactation Puberty Postpuberty 
PND 1 PND 21 PND 50 
Section 
PND 80 
Section 
Hormonal decline 
15 
 
The first subgroup was sacrificed on postnatal day (PND) 50 (puberty), the second 
on PND 80 (adult). The other three subgroups of each nutrition group were 
ovariectomized at day 80. After 14 days of hormonal decline an uterotrophic assay 
was performed at day 94. These rats then received 17β-estradiol (E2; 7.8 µg/kg 
BW/day), genistein (GEN; 19.6 mg/kg BW/day), or the vehicle solely (OVX) 
subcutaneously for three days before they were sacrificed (PND 97). The estrogenic 
compounds were solved in 20 % DMSO/peanutoil. 
 
Diets 
The animals had free access to one of three diets containing different amount of 
ISO: an ISO-depleted diet (IDD; Ssniff R/M-H Ssniff GmbH, Soest, Germany), an 
ISO-rich diet (IRD; Harlan Teklad 8604 rodent diet, Harlan Winkelmann, Borchen, 
Germany), or an IDD supplemented with 700 µg GEN (GRD; 4´,5,7-
trihydroxyisoflavone, LC Laboratories, Woburn, USA). The compositions of the diets 
are depicted in Table 1. 
 
      IDD   IRD 
Brutto energy (kcal/g)   4   3.93 
Metabolizable Energy (kcal/g) 3   3.3 
Crude protein (%)   19.3   24.0 
Crude fat (%)    3.3   4.0 
Crude fiber (%)   4.4   4.5 
N-free extractive (%)   55.1   46.64 
C18:2 (Linols) (%)   1.49   1,87  
 
Tab. 1: Composition of the different diets. IDD = Isoflavone depleted diet (Ssniff). IRD = Isoflavone rich 
diet (Harlan Teklad) 
 
Indicated by the manufactures the protein source in the Ssniff R/M-H diet is cereals 
and potatoes, in the Harlan Teklad 8604 rodent diet soy, fish meal and yeast. The 
choice of these diets and the respective ISO content was based on results of former 
studies. In previous experiments of our laboratory, an oral dose up to 50 mg GEN 
per kg did not affect the uterine wet weights (Diel et al., 2001), while an oral GEN 
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dose of 100 mg/kg results in effects on several tissues in the animals (Seibel et al., 
2009). This very high dose is representative for an exposure scenario depicting 
supplementation with soy extracts or pure GEN. In contrast, in the used IRD the 
source of the high content of ISO is dehulled soybean meal. Based on the data from 
previous studies, where ISO-content of rodent diets from different vendors was 
analysed and compared (Degen et al., 2002), the ISO-rich diet (IRD) from Harlan-
Winkelmann was chosen because of its high ISO content. This diet depicts more an 
exposure scenario of an ISO-rich nutrition like consumed in Eastern Asia. 
Given the ISO content and daily food consumption (18–20 g/d/animal), the average 
oral intake resulted in 13.5 mg/kg BW for DAI and 15.7 mg/kg BW for GEN per adult 
animal in the IRD group, 42 mg/kg BW per adult animal and day for GEN in the 
GRD group, and less than 0.1 mg DAI or GEN/kg BW per day in the IDD group. 
 
ISO Standards 
The ISO aglycones daidzein, genistein, glycitein, their corresponding 7-O-ß-
glucosides daidzin, genistin, glycitin, as well as 6’’-O-acetyl-daidzin, -genistin and -
glycitin and 6’’-O-malonyl-daidzin, -genistin and -glycitin were obtained from Wako 
Chemicals GmbH (Neuss, Germany). Purity of the standard compounds was not 
less than 97 % (determined by HPLC/DAD analysis at 250 nm). 
 
Tissue preparation 
After weighing, animals were decapitated and blood was collected. The mammary 
gland and the uterus were removed and the uterus wet weights were determined. 
Specimen of each tissue were either snap frozen in liquid nitrogen for mRNA and 
protein preparation or fixed and embedded in paraffin for histological analysis. 
 
Quantification of ISO derivatives in the diet by HPLC/DAD analysis 
The pelleted diets IRD and IDD were crushed using mortar and pestle. Approx. 250 
mg of an accurately weighted sample of each homogenized diet powder were 
vortexed for 30 s in exactly 40 mL 65 % (v/v) methanol and extracted gently for 60 
min at room temperature using an overhead rotation shaker. The suspensions were 
centrifuged at 8600 g for 5 min and filtered using 15 mm 0.45 um PTFE syringe 
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filters. The filtrate was diluted by pipetting 1 ml of the solution into a 50 ml graduated 
flask and make up to the mark with 65 % (v/v) methanol.  
The LC-DAD analyses were performed on a Shimadzu LC system equipped with a 
controller (CBM-20A), a degasser (DGU-20A3), two pumps (LC-20AD), an 
autosampler (SIL-20AC HT), a column oven (CTO-20AC) and a diode array detector 
(SPD-M20A). The LC system was controlled by the software LC solution 1.24. 
Separation of the ISO derivatives was performed on a Phenomenex Kinetex PFP 
column (3.0 mm internal diameter, 100 mm length, 2.6 µm) with an oven 
temperature of 35°C. Solvent A was 0.1 % (v/v) formic acid in bidest. water and 
solvent B was acetonitrile (VWR, LC grade). Flow rate was 0.7 ml/min, the injection 
volume 10 µl. The LC gradient started with an initial period of 3 min at 10 % B, 
increasing linearly to 45 % B at 12 min, and finally to 100 % at 12.5–15.5 min, re-
equilibrating the system in a 7.5 min postrun (10 % B). Eluent was monitored 
between 200 and 500 nm using diode array detection. Peaks were integrated at 250 
nm. The identity of each compound was confirmed by the retention time and the UV-
Vis spectra. The limit of quantification (LOQ) and lowest calibration point was 0.8 
nmol for all target analytes. 
 
Measurement of the GEN and DAI serum concentrations 
GEN and DAI were quantified in the serum samples (100 µl) by capillary gas 
chromatography-mass spectrometry (1200 Varian Triple Quadruole system) as 
previously described in detail (Rufer et al., 2008) with the exception that the 
derivatization of the ISO was performed using N-(tert-butyldimethylsilyl)-N-
methyltrifluoroacetamide with 1 % tert-butyldimethylchlorosilane (Sigma-Aldrich, 
Taufkirchen, Germany). The two stable isotopically labeled ISO, [3,4,8-
13C3]daidzein, and [3,4,1′-13C3]genistein (Nigel Botting, University of St Andrews, 
UK) were used as internal standard compounds. 
 
Western Blot analysis 
Frozen mammary gland tissue specimen was powdered and homogenized in buffer 
(623.5 nM Tris pH 8 EDTA) containing enzyme inhibitors (5 mg/ml aprotonin, 5 
mg/ml leupeptin, 1 mg/ml pepstatin-A, 5 mg/ml antipain, 100 mM pefac in 0.5 M 
EDTA pH 8). Protein concentrations were measured with the method of Lowry 
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(Lowry et al., 1951) (Dc Protein Assay, Bio-Rad). Equal amounts of samples (40 µg 
protein) were loaded on 4–12 % Bis-Tris NUPAGE® Novex Gels (Invitrogen Life 
Technologies, Karlsruhe, Germany). For the electrophoresis the MES Buffer was 
used (Invitrogen Life Technologies, Karlsruhe, Germany). After electrophoresis the 
proteins were transferred onto nitrocellulose membranes and blocked with 5 % BSA 
in phosphate buffered saline solution at room temperature for 1 hour. The protein 
expressions of actin and PCNA were quantitative detected using specific antibodies 
(Anti Actin A 5060, Sigma-Aldrich, Taufkirchen, Germany; Anti PCNA M0879, Dako, 
Glostrup, Denmark). As species specific antibodies the Horseradish Peroxidase 
conjugated Polyclonal Rabbit Anti Mouse (Dako, Glostrup, Denmark) and Polyclonal 
Swine Anti Rabbit (Dako, Glostrup, Denmark) were used. The visualization of the 
blot signals was performed with the chemiluminescent POD-substrate and a 
Fluorchem Luminescent Imager. The densitometrical analysis was performed with 
the Image J program (ImageJ 1.33u, National Institute of Health, USA, 
http://rsb.info.nih.gov/ij/). Actin was used as reference protein and served as loading 
control. 
 
Immunhistochemical analysis 
The paraffin-embedded mammary glands were cut in 7 µm sections and were 
mounted on slides coated with polylysine (Menzel Gläser, Hilden, Germany). The 
mammary gland tissue was cleared, hydrated and antigen retrieval was performed 
using TrisEDTA. After overnight incubation in TrisEDTA at 60°C, the mammary 
gland tissues were washed four times with phosphate buffered saline (PBS). Then 
the tissue was incubated with a solution consisting of 0.5 M ammoniumchloride in 
0.25 % Triton-X/PBS for 10 min. After four wash steps the unspecific binding sites 
were blocked with 5 % BSA for one hour. Then the mammary gland tissue sections 
were incubated with the first antibody (Anti PCNA M0879, Dako, Glostrup, Denmark; 
Anti PR 1408, Beckman Coulter, Marseille, France; Anti ERβ (H-150) sc-8974, 
Santa Cruz Biotechnology, Santa Cruz, USA) at 4°C overnight. After 4 washsteps 
the second antibody (Polyclonal Rabbit Anti Mouse biotinylated, Dako, Glostrup, 
Denmark; Polyclonal Goat Anti Rabbit biotinylated, Dako, Glostrup, Denmark) was 
incubated for one hour at room temperature. To visualize the binding of the PCNA 
antibody, the tissue sections were incubated with FluoroLinkTM CyTM3 labelled 
streptavidin (PA 43001, Amersham Biosciences). To depict the percentage of 
proliferating nuclei, all nuclei were stained with DAPI (4´,6-Diamidino-2-
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phenylindole, D 9542, Sigma-Aldrich, Taufkirchen, Germany). Per slide 300 nuclei 
were analysed for PCNA expression and the percentage of PCNA-positive nuclei 
was calculated. In order to visualize the binding of the PR and the ERβ antibody, the 
tissue sections were incubated with Streptavidin-Biotinylated Horseradish 
Peroxidase Complex (RPN1051, GE Healthcare, Buckinghamshire, UK) and stained 
with Diaminobenzidin (DAB). 300 nuclei were counted per slide, and the percentage 
of PR positive nuclei was calculated. Staining of ERβ was utilized by densitometrical 
analysis using the Image J program (ImageJ 1.33u, National Institute of Health, 
USA, http://rsb.info.nih.gov/ij/). 
 
RNA preparation 
Frozen mammary gland tissue specimen was powdered and homogenized in 
TRIzol®. Total RNA was isolated from cells using the TRIzol® (Invitrogen Life 
Technologies, Karlsruhe, Germany) standard protocol (Chomczynski & Sacchi, 
1987) followed by cDNA synthesis with the Quantitect® Reverse Transcription Kit 
(Quiagen, Hilden, Germany). 
 
Real-time RT-PCR 
Quantitative Real-time RT-PCR was performed in the MxPRO (Stratagene) with 
Platinum® Taq DNA Polymerase (Invitrogen, Karlsruhe, Germany). SybrGreen I® 
was used as detection dye. The Cytochrome-C-oxidase subunit 1A (1A) was used 
as housekeeping gene, and the expression of all genes was normalized to 1A. 
Specific primers were designed with the primer3 software (Whitehead Institute for 
Biomedical Research, Cambridge, USA) based on the cDNA sequences available at 
the EMBL database: 1A: up: 5’-CGTCACAGCCCATGCATTCG-3 ‘, dw: 5’-
CTGTTCATCCTGTTCCAGCTC-3 ‘; PR: up: 5’-CATGTCAGTGGACAGATGCT-3’ ‘, 
dw. 5’-ACTTCAGACATCATTTCCGG-3 ‘; PS2: up: 5´-
GGAAAGGGTTGCTGTTTTG-3´, dw: 5´-ACAGGTGTGTATGAAGCAGGTG-3´; 
ERα: up: 5´-GGAAGCACAAGCGTCAGAGAGAT-3´, dw: 5´-
AGACCAGACCAATCATCAGGAT-3´. The PCR program consisted of a first 
denaturation step at 95°C for 4 min, followed by 45 cycles of 30 sec at 94°C, 30 sec 
at 60°C and 30 sec at 72°C. The fluorescence was quantified during the 72°C 
elongation step and the product formation was confirmed by melting curve analysis 
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(55–95°C). For calculation of relative rates of gene expression the ∆∆CT method 
was used (Pfaffl, 2001). Gene expressions were compared to those of control 
animals fed with the ISO-free diet.  
 
Statistical analysis 
Statistical analysis was performed using the SPSS Statistical Analysis System, SAS, 
Version 12.0. All data are expressed as arithmetic means with their standard 
deviations. First a global Kruskal Wallis-H-Test was performed to analyse if there 
are significant differences between the groups. In case of differences, a Mann-
Whitney U-Test was additionally performed to identify the groups with statistical 
significant variance. Statistical significance was established at p < 0.05. 
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Results 
The experimental design of this study is depicted in Figure 1. The animals of this 
experiment received one of three different diets. The IDD contains no detectable 
amounts of ISO (< 10 µg/g). The IRD contains 248 µg GEN/g, 213 µg DAI/g and 59 
µg GLY/g (each calculated as aglykone). ISO in the diet were mainly (> 90 %) 
present as the respective glucoside and malonyl-glucoside derivatives. A detailed 
analysis of the ISO derivatives in the diet is given in Table 2. The GRD based on an 
IDD, enriched with 700 µg GEN/g (Hertrampf et al., 2009a). 
 
ISO derivative  MW  mean value mean value calculated  
      as 
      aglycone  
[g/mol] µg/g IRD µM/g IRD µg/g IRD 
Daidzein   254.24  8.83  0.035  8.83 
Genistein   270.24  8.59  0.032  8.59 
Glycitein   284.27  n.d.  -  - 
Daidzin   416.38  191.96  0.461  117.21 
Genistin   432.38  210.63  0.487  131.64 
Glycitin   446.40  58.82  0.132  37.46 
6''-O-Acetyl-Daidzin  458.41  48.21  0.105  26.73 
6''-O-Acetyl-Genistin  474.41  51.18  0.108  29.17 
6''-O-Acetyl-Glycitin  488.44  12.68  0.026  7.39 
6''-O-Malonyl-Daidzin  502.42  119.25  0.237  60.32 
6''-O-Malonyl-Genistin 518.42  150.04  0.289  78.19 
6''-O-Malonyl-Glycitin  532.45  26.28  0.049  14.04 
 
Sum of daidzein derivatives calculated as Daidzein aglycone in µg/g IRD 213.09 
Sum of genistein derivatives calculated as genistein aglycone in µg/g IRD 247.59 
Sum of glycitein derivatives calculated as glyciteinaglycone in µg/g IRD  58.89 
 
Tab. 2: Content of ISO derivatives in the ISO-rich diet (IRD). (nd = not detected) 
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Serum concentrations of GEN and DAI were measured at PND 50 and PND 80 
(Tab. 3). As expected, the serum concentrations of GEN and DAI significantly 
increased with the increasing ISO content in the diet. No differences were detected 
between PND 50 and PND 80.  
 
DAI (µM)  GEN (µM) 
PND 50 IDD  n.d.  0.24 ± 0.01  
   IRD  1.70 ± 0.67 1.09 ± 0.13* 
   GRD   n.d.  2.55 ± 0.23**++ 
PND 80  IDD  0.11 ± 0.24 0.26 ± 0.02 
IRD  2.15 ± 1,75 1.17 ± 0.31* 
GRD  0.21± 0.29 2.49 ± 0.44**+ 
 
Tab. 3: Genistein and Daidzein concentration (in µM) in the blood serum of 50 (PND 50) and 80 (PND 
80) days old rats. * = sign. vs. IDD (p < 0.05),** = sign. vs. IDD (p < 0.01), + = sign. vs IRD (p < 0.05), ++ 
= sign. vs. IRD (p < 0.01); (Kruskal-Wallis H-Test followed by a Mann-Whitney U-Test) 
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As depicted in Table 4, neither treatment nor nutrition had influenced the body 
weights or the heart weights. The wet weights of the uteri significantly increased 
after treatment with E2 in all groups compared to their OVX groups. Additionally, IRD 
and GRD animals treated with E2 showed a significant increase in the wet weights of 
the uteri compared to the IDD group. Treatment with GEN had no significant effect 
on uterine wet weights in any group. 
 
 
Body Weight  Uterus  Heart  
(g)    (mg/kg BW) (mg/kg BW) 
PND 50  IDD  156 ± 7  1058 ± 73  3971 ± 178 
IRD  159 ± 6  1687 ± 171  3943 ± 283 
GRD  170 ± 7  1395 ± 223  3912 ± 265 
PND 80  IDD  251 ± 14  1110 ± 179  3347 ± 272 
  IRD  227 ± 3  1254 ± 222  3199 ± 215 
GRD  249 ± 10  1237 ± 206  2970 ± 272 
OVX  IDD  296 ± 7  469 ± 23  3370 ± 104 
IRD  299 ± 10  636 ± 39  3365 ± 122 
GRD  294 ± 11  553 ± 43  3273 ± 34 
E2  IDD  269 ± 13  1804 ± 124 **  3443 ± 112 
  IRD  286 ± 10  5620 ± 750 **++ 3533 ± 57 
  GRD  295 ± 6  5104 ± 372 **++ 3470 ± 68 
GEN  IDD  264 ± 8  527 ± 44  3615 ± 124 
  IRD  280 ± 10  712 ± 68  3475 ± 80 
  GRD  320 ± 10  691 ± 71  3306 ± 117 
 
Tab. 4: Body weights (g), uterus wet weights (mg/kg BW), heart weight (mg/kg BW). ** p < 0.01 vs. 
IDD OVX; ++ p < 0.01 vs. IDD E2; (Kruskal-Wallis H-Test followed by a Mann-Whitney U-Test) 
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To evaluate the influence of ISO on proliferation of the mammary gland, the protein 
expression of the Proliferating Cell Nuclear Antigen (PCNA) was determined. 
Western Blot analysis of PCNA showed a significant increase in the GRD fed 
animals compared to the IDD and IRD group at PND 50, but no differences were 
detected in PCNA expression at PND 80 in intact animals (Fig. 2). 
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Fig. 2: Protein expression of PCNA in the mammary gland of intact 50 and 80 days old rats. Depicted 
is a representative Western Blot of PCNA in intact animals and the quantitative analysis of the Western 
blots. IDD PND 50 served as control and were set to one. The bars shown are mean +SD. Six rats 
were included to each group. * = sign. vs. IDD PND 50 (p < 0.05); + = sign. vs. IRD PND 50 (p < 0.05); 
(Kruskal-Wallis H-Test followed by a Mann-Whitney U-Test) 
 
To investigate the influence of in utero and postnatal exposure to ISO on the 
sensitivity of the mammary gland towards estrogen exposure mammary gland tissue 
obtained from rats used in an uterotrophic assay was examined. Immunfluorescence 
analysis of the mammary gland of OVX animals showed no differences in the PCNA 
expression in the OVX animals of either diet, whereas treatment with E2 led to an 
increased proliferation rate (Fig. 3 A). No differences could be seen in GEN treated 
groups.  
+ 
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Fig. 3: Protein expression of PCNA in the mammary gland of 97 days old ovariectomized animals. A 
Representative pictures of Immunhistochemical stained sections of the mammary gland. Proliferating 
nuclei were stained with PCNA labelled with Cy3 (black). Stained grey with DAPI are all nuclei. B 
Quantitative analysis of PCNA staining. C Depicted is a representative Western Blot of PCNA in the 
mammary gland of OVX rats and the quantitative analysis of the Western blots. IDD OVX served as 
control and were set to one. The bars shown are mean +SD. Six rats were included to each group. * = 
sign. vs. IDD OVX (p < 0.05); + = sign. vs. IDD E2 (p < 0.05); (Kruskal-Wallis H-Test followed by a 
Mann-Whitney U-Test) 
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Quantitative analysis showed a significant increase of PCNA expression in the E2 
treated groups compared to the OVX groups. Interestingly, after pre-exposure to 
IRD and GRD the E2 stimulation of PCNA protein expression detectable in IDD was 
found to be significantly diminished (Fig. 3 B). The observation was verified with 
western blot analysis. As in the immunfluorescence analysis, no differences in OVX 
and GEN treated animals were detected, but a significant increase in PCNA 
expression in IDD fed animals treated with E2 (Fig. 3 C). The IRD showed no 
increase in PCNA expression after E2 treatment, while in the GRD group an 
increase in PCNA expression was detected. 
A well established marker for estrogen action in the mammary gland is the 
progesterone receptor (PR) bearing an estrogen response element (ERE) in its 
promoter (Kraus et al., 1993). Immunhistochemical analysis of PR expression in the 
mammary gland revealed only a slight expression in OVX and GEN treated groups. 
E2 treatment results in a significant increase of PR staining in all groups (Fig. 4 A). 
Quantitative analysis of the immunhistochemical staining indicated that the increase 
was significant higher in the animals which received in utero and postnatal an IDD 
(Fig. 4 B). This observation was confirmed by semi-quantitative analysis of PR 
mRNA expression (Fig. 4 C). None of the GEN-treated groups showed differences 
in the mRNA expression of PR compared to the OVX groups. 
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Fig. 4: Expression of the progesterone receptor (PR) in the mammary gland of 97 days old 
ovariectomized rats. A Protein expression of the PR. Depicted are representative pictures of 
immunhistochemical stained sections of the mammary gland. B Quantitative analysis of PR staining. C 
mRNA expression of the PR in the mammary gland. IDD OVX served as control and were set to one. 
The bars shown are mean +SD. Six rats were included to each group. * = sign. vs IDD OVX (p < 0.05); 
+ = sign. vs. IDD E2 (p < 0.05); (Kruskal-Wallis H-Test followed by a Mann-Whitney U-Test) 
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Beside PR, the expression of the estrogen receptor α (ERα) and the PS2 gene was 
measured in the mammary gland using real-time RT-PCR. For ERα it has been 
demonstrated that mRNA and protein expression show a good regulation in this 
tissue (Schams et al., 2003). As shown in Figure 5 A, in utero and postnatal 
exposure to an IRD showed only a slight increase of ERα mRNA expression in OVX 
animals, while treatment with E2 resulted in a significant increase in ERα expression 
in the animals fed in utero and postnatal an IDD compared to those fed an IRD or 
GRD. PS2 expression (Fig. 5 B) was increased in OVX IRD and GRD animals 
compared to OVX IDD. E2 treatment resulted in a significant decrease of PS2 
expression in the IDD group but in a strong stimulation of PS2 expression in the IRD 
and GRD group. In response to GEN treatment, no significant differences could be 
measured. 
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Fig. 5: mRNA expression of the estrogen receptor α (ERα) (A) and PS2 (B) in the mammary gland of 
97 days old ovariectomized rats. IDD OVX served as control and were set to one. The bars shown are 
mean +SD. Six rats were included to each group. * = sign. vs. IDD OVX (p < 0.05); + = sign. vs. IDD E2 
(p < 0.05); (Kruskal-Wallis H-Test followed by a Mann-Whitney U-Test) 
 
To reveal differences in the expression patterns of the estrogen receptors, the 
protein expression of estrogen receptor β (ERβ) were analysed by 
immunhistochemistry (Fig. 6). ERβ staining of the mammary gland showed only 
marginal differences of its expression in the OVX groups (Fig. 6 A). After treatment 
with E2, an increase of expression could be detected in IRD and GRD animals but 
not in animals receiving an IDD. This observation was confirmed by densitometrical 
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analysis (Fig. 6 B). The highest expression of ERβ was measured after treatment of 
GRD animals with GEN. 
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Fig. 6: Expression of the estrogen receptor β (ERβ) in the mammary gland of 97 days old 
ovariecotmized rats. A Protein expression of the ERβ. Depicted are representative pictures of 
immunhistochemical stained sections of the mammary gland. B Densitometric analysis of ERβ staining. 
IDD OVX served as control and were set to one. The bars shown are mean +SD. Six rats were 
included to each group. * = sign. vs. IDD OVX (p < 0.05); + = sign. vs. IDD E2 (p < 0.05); (Kruskal-
Wallis H-Test followed by a Mann-Whitney U-Test) 
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Discussion: 
Epidemiological studies suggest that soy consumption is associated with a lower 
risk of developing breast cancer in the Asian population. It is hypothesized that the 
exposure to ISO has to start before adolescence sets in to exert protective effects. 
Studies investigating the effects of in utero and postnatal exposure to ISO are still 
inconsistent (Warri et al., 2008). The present study was performed to analyse the 
impact of in utero and postnatal exposure to ISO on the mammary gland. In order to 
make sure that the offspring was exposed to ISO already in utero the dams received 
one of three different diets, respectively. The IRD was chosen because of its high 
ISO content, as the aim of the study was to investigate estrogenic effects of an ISO-
rich diet on the mammary gland. The diets differ in protein and fat content, but in 
order that the IRD exert similar effects as the GRD, we can be sure that these 
differences did not influence the estrogenic response of the mammary gland (Tab. 
1). The long-term exposure to IRD and GRD consequently resulted in increased 
serum concentrations of GEN (Tab. 3). In case of the IRD increased concentrations 
of DAI and its colonic microbiota-derived metabolite equol have additionally to be 
taken into account. Unfortunately we have not determined the serum equol 
concentration in our study, but its remarkable formation in rodents is well described. 
For instance, Poulsen et al. found almost equally high DAI and equol plasma 
concentrations in ovariectomized rats fed a diet supplemented with DAI (Poulsen et 
al., 2009). 
As we observed a strong influence of ISO and GEN exposure on mammary gland 
biology the question arises about a potential developmental origin of these effects. 
Previous studies suggested that the placental transfer of ISO is high, whereas the 
lactational transfer is low to negligible (Doerge, 2011; Doerge et al., 2006). On the 
other hand, even if the lactational transfer seems to be low, quite significant 
alterations of the proteome can be achieved in mammary glands of prepubertal 
animals which were feed by lactating dams which were exposed to a diet containing 
250 ppm of GEN (Wang et al., 1996). Applying these findings to our study it has to 
be assumed that in utero exposure most likely contributes to the effects observed, 
however, a contribution to the effects through lactational exposure cannot be 
excluded. 
As shown in Table 4 and as reported before (Hertrampf et al., 2009a), no 
differences in the uterine wet weights could be detected in 50 and 80 days old intact 
animals, indicating a low estrogenic potential of the different diets. 
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In the first part of the present study the mammary gland was analysed at postnatal 
day (PND) 50 and at PND 80. As shown in Figure 2 no differences could be 
observed between the different dietary groups of 80 days old adult intact animals, 
whereas significant differences were observed at day 50 (Fig. 2), where PCNA 
expression was strongly stimulated in the GRD group. A recent review on xenobiotic 
exposure and breast cancer risk in animal models came to the conclusion that 
acceleration or delay of glandular maturation appears to be a crucial point regarding 
whether exposure to a xenobiotic leads to prevention or increases the risk to 
develop breast cancer (Jenkins et al., 2012). A possible explanation for our effect 
may indeed be an acceleration of the differentiation program of the mammary gland 
in response to GEN treatment which has already been shown by other groups 
(Warri et al., 2008). In fact, in a recent neonatal exposure study a transient, 
statistically not significant increase in Ki-67 immunoreactivity, occurring earlier than 
the increase in PCNA immunoreactivity in our study, was reported in response to 
GEN which decreased statistically significant later in life (Wang et al., 1996). 
To study if in utero and postnatal exposure to IRD or GRD alters the estrogen 
responsiveness of the mammary gland, in OVX animals serving as a model system 
of the situation in postmenopausal woman, an uterotrophic assay was performed. 
As shown in Table 4, E2 exposure always resulted in an increase of uterine wet 
weights, but the uterine weights of IRD and GRD were significantly higher than in 
IDD animals. These data indicate that the estrogen responsiveness of the uterus 
was highly modulated by long-term ISO exposure. Interestingly, no influence on 
uterine proliferation could be observed between the dietary groups after E2 
treatment, whereas the water homeostasis was highly affected. Möller et al. 
speculated that the methylation pattern of genes associated with transcellular water 
transport in the uterus was changed after in utero and postnatal ISO exposure 
(Moller et al., 2010). 
In the mammary gland of OVX IRD, IDD and GRD, similar to intact 80 days old 
animals, there were no significant differences in PCNA expression. In order to 
stimulate cell-proliferation in mammary gland tissue, animals were treated with E2 for 
3 days subcutaneously (s. c). In line with published data (Hertrampf et al., 2006; 
Rimoldi et al., 2007; Rachon et al., 2008) the protein expression of PCNA in the 
mammary gland increased significantly in response to the E2 treatment in all dietary 
groups. In contrast, exposure to GEN had no effect in treatment groups. This 
confirms a previous study from our laboratory (Hertrampf et al., 2006), where neither 
s. c. nor oral treatment with GEN affected the PCNA expression and only slight 
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effects on the PR expression in the mammary gland of adult OVX Wistar rats could 
be observed. 
A key result of the study presented here is the observation that the E2 induced 
stimulation of mammary gland PCNA expression was significantly lower following 
dietary exposure of animals in IRD and GRD groups if compared to IDD fed animals. 
This strengthens the hypothesis that pretreatment with ISO accounts for a lower 
sensitivity of mammary gland tissue towards estrogen treatment. 
A possible explanation for this altered sensitivity may be the anatomy of the 
mammary gland. Several studies have investigated the effects of in utero, perinatal 
and prepubertal exposure towards ISO on the morphology of the mammary gland 
(Warri et al., 2008). Whereas results obtained for in utero, perinatal and prenatal 
exposure scenarios are not consistent, it has been shown that pre-pubertal 
exposure to GEN increases mammary tissue differentiation by leading to a reduction 
in the number of terminal end buds (TEB) and an increase in the number of 
differentiated lobules (Hilakivi-Clarke et al., 1999; Cotroneo et al., 2002; 
Lamartiniere et al., 2002; Cabanes et al., 2004). It is possible that the lack of 
increased proliferation after treatment with E2 in the IRD fed group is a result of a 
reduced number of TEB in the mammary gland. 
Taken further, the present results show that not only proliferation, but also the 
expression of a variety of estrogen sensitive genes is altered. The expression 
patterns of the PR (Fig. 4) and ERα (Fig. 5 A) are very similar to those of the PCNA 
expression. Both receptors have been implicated in the etiology and the 
pathogenesis of breast cancer. In the normal mammary gland, progesterone is 
needed for lobulo-alveolar development and ductal branching, whilst estradiol 
regulates ductal elongation. Russo et al. (Russo et al., 1999) reported that the 
content of ERα and PR in the lobular structures in the breast is directly proportional 
to the rate of cell proliferation. In normal resting mammary glands, the percentage of 
ERα-positive cells is generally low, and increases in proliferative benign disease, 
particularly when associated with atypia (Roger et al., 2000). Additionally, the dual 
expression of the ER and the proliferating marker Ki-67 seemed to be the 
manifestation of an important early molecular change in the development of 
malignant breast neoplasia (Shoker et al., 1999). Furthermore, an important function 
of the ERα in the epithelium is the induction of PR (Saji et al., 2000), and it is known 
that co-expression of both is inversely associated with breast cancer risk among 
postmenopausal women (Lagiou et al., 2009). 
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Remarkable is the observation regarding the regulation of ERβ by E2 in the different 
nutritional groups. It is hypothesized that one function of ERβ is to counter that of 
ERα (Saji et al., 2005). In vitro studies showed a reduction in estrogen stimulated 
proliferation after introduction of the ERβ expression vector into representative ERα-
positive breast cancer cell lines MCF-7 and T47D (Omoto et al., 2003; Strom et al., 
2004). In line with these observations is our finding that the reduced sensitivity of the 
mammary gland to respond to E2 treatment by proliferation in GRD and IRD fed 
animals was associated with an elevated expression of ERβ (Fig. 6) and a 
decreased expression of ERα (Fig. 5 A). Also notable is the fact that the expression 
pattern of the PS2 gene is similar to that of ERβ (Fig. 5 B). There are speculations 
that high expression levels of PS2 may be protective against the development of 
breast cancer. Transgenic mice, which overexpress PS2 in their mammary gland do 
not develop tumors (Tomasetto et al., 1989). Our observation that PS2 expression 
can be induced by ISO is in line with results of Hargreaves et al. (Hargreaves et al., 
1999) showing that treatment of premenopausal women with dietary soy 
supplements for two weeks results in an increased expression of PS2 in the breast. 
Interestingly, the control of the PS2 gene also depends upon epigenetic factors 
(Chatagnon et al., 2010; Ribieras et al., 1998) as the tissue-specific methylation of 
its proximal promoter/enhancer region correlates directly with its expression (Martin 
et al., 1995; Martin et al., 1997). The increased mRNA expression of PS2 in the IRD 
fed group could lead to the suggestion that ISO could exert their protective effects 
via epigenetic modulation. Indeed, recently a variety of studies have shown 
epigenetic changes induced by ISO (Guerrero-Bosagna et al., 2008; Li et al., 2009; 
Molinie & Georgel, 2009) having positive effects on breast or prostate cancer. 
In summary, our results provide evidence that in utero and postnatal exposure to a 
diet rich in soy ISO in their natural chemical form as β-glucoside conjugates as well 
as to a diet solely enriched with GEN in the aglycone form may alter the gene 
expression of the mammary gland, which consequently results in a changed 
sensitivity of this tissue towards estrogens. This observation leads to the hypothesis, 
that in utero and postnatal ISO exposure may reduce the risk to develop breast 
cancer in a protective manner. To clarify the underlying mechanisms, i.e. if the 
altered susceptibility of the mammary gland is a result of epigenetic mechanisms 
during the development further studies are needed. 
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CHAPTER THREE 
 
 
Lifelong exposure to isoflavones influences the gene expression in the small 
intestine of female rats* 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
___________________________________________________________________ 
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Abstract 
Nutritive uptake of isoflavones (ISO) is discussed as one factor responsible for the 
low incidence of gastrointestinal cancer in Eastern Asia. Our aim was to investigate 
the effects of lifelong ISO exposure on the tissue homeostasis and estrogen
 
sensitivity in the small intestine of female rats. 
Animals were exposed to either an ISO-free diet (IDD), ISO-rich diet (IRD) or an IDD 
supplemented solely with genistein (GRD). After sacrifice at postnatal days 25 (PND 
25), 50 (PND 50) and 80 (PND 80), the expression of molecular markers for 
proliferation (PCNA), intestinal tumor protection (p63, PS2) and estrogen receptor α 
and β (ERα, ERβ) was analysed in the small intestine. Furthermore, IDD, IRD and 
GRD rats were ovariectomized (PND 80) and treated either with vehicle (OVX) or 
estradiol (E2) for 3 days. 
Lifelong exposure to IRD or GRD results in increased expressions of PCNA and 
PS2 at PND 50 and 80. In ovariectomized animals p63 expression was lower in IRD 
and GRD, whereas E2 treatment resulted in a decrease of p63 in all groups. IRD 
and GRD OVX had lower ERα but higher ERβ expression. The expression of PS2 
was increased in GRD OVX, but decreased in all dietary groups after treatment with 
E2. 
In summary our results provide evidence that lifelong exposure to ISO improves 
intestine homeostasis, and modulate the expression of molecular markers related to 
tumor protection and the responsiveness of this tissue towards E2. Consequently, 
the susceptibility of this tissue to develop cancer is affected. 
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Introduction 
The incidence of gastrointestinal cancer is much lower in Eastern Asia compared to 
Europe or USA (Adlercreutz & Mazur, 1997; Martinez, 2005). Apart from other 
factors epidemiological and migration studies suggests that the soy rich diet 
containing high amounts (20–50 mg isoflavones per day) of the isoflavones (ISO) 
genistein (GEN) and daidzein (DAI) reduces the cancer susceptibility in these 
countries (Budhathoki et al., 2011; Adlercreutz, 1990; Lechner et al., 2005). ISO are 
naturally occurring soy compounds, and are able to bind to the estrogen receptor 
(ER) and initiate estrogenic action.  
Via binding to the ER estrogens are able to mediate the tissue homeostasis in the 
intestine, which is usually characterized by a steady state of proliferation and 
apoptosis (Lechner et al., 2005; Wada-Hiraike et al., 2006; Weige et al., 2009). A 
shift in this homeostasis is an initial event in tumor progression (Koornstra et al., 
2003). That estrogens have an impact on bowel cancer has been described in 1996. 
Di Domenico showed that the growth of the colon cancer cell line Caco-2 increased 
after treatment with Estradiol (E2) (Di Domenico et al., 1996). It has been shown that 
long-term supplementation with synthetic E2 lowers the risk of developing colorectal 
cancer (Nelson et al., 2002; Chlebowski et al., 2004). Many studies regarding the 
health effects of hormone replacement therapy (HRT) showed protective effects of 
estrogen treatment towards the intestine (Nelson et al., 2002; Wada-Hiraike et al., 
2006). 
The predominantly ER in the intestine is the ERβ (Kuiper et al., 1997; Campbell-
Thompson et al., 2001; Konstantinopoulos et al., 2003). Previous studies conducted 
with ERβ-selective ligands or ERβ-Knockout mice showed that activation of the ERβ 
is involved in cellular anti-inflammatory pathways and tissue homeostasis in the 
colon (Harris et al., 2003; Wada-Hiraike et al., 2006; Weige et al., 2009). The 
importance of these effects of the ERβ additional becomes apparent by the 
observation that its expression is significantly reduced in colon cancer cell lines 
(Konstantinopoulos et al., 2003; Jassam et al., 2005; Martineti et al., 2005). In this 
context ERβ-selective compounds seem to be useful in treating disease in the 
intestinal tract via activating the ERβ. 
Due to the specifically high binding affinity of ISO to the ERβ, GEN may serve as a 
potential regulator of intestinal tissue homeostasis. The action of ISO depends on 
several factors. Numerous studies have led to the suggestion that the time of ISO 
exposure is important for their protective effects (Cabanes et al., 2004; Padilla-
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Banks et al., 2006). Additionally, the action of ISO differs dependent on the estrogen 
status. The group of Hwang showed that in the presence of premenopausal level of 
E2 ISO act as estrogen antagonists and thus inhibits estrogenic action, whereas at 
lower E2 doses which occur in postmenopausal women, ISO act as estrogen 
agonists (Hwang et al., 2006).  
While many findings on these effects are available, the data regarding lifelong 
effects of ISO on homeostasis and estrogen sensitivity of the intestine are still 
limited. The purpose of this study was to evaluate the influence of lifelong ISO or 
GEN exposure on tissue homeostasis of the female intestine. Additionally, we aimed 
to analyse whether ISO influences the estrogen responsiveness of this tissue. As 
molecular read out the mRNA expression of markers for proliferation (PCNA), tumor 
protection (p63 and PS2) and of ERα and ERβ was determined in the small 
intestine. 
  
 42 
 
Materials and Methods: 
Experimental animals and study design 
All animal handling and experimental conditions were carried out according to the 
“Institutional Animal Care and Use Committee guidelines”, regulated by the German 
federal law for animal welfare. 
Wistar rats were obtained from Janvier (Le Genest St Isle, France) and kept under 
controlled conditions of temperature (20°C ± 1), relative humidity (50–80 %) and 
illumination (12 h dark, 12 h light). Female rats were mated and the dams were fed 
one of three diets during pregnancy and nursing. After weaning the female offspring 
(n = 30 each dietary group) were fed the appropriate diet. The animals had ad 
libitum access to the diets and water. Each dietary group was further divided into 
five subgroups (n = 6 each group). The first subgroup was sacrificed on postnatal 
day (PND) 25 (childhood), the second on PND 50 (puberty), and the third on PND 
80 (adult). The other two subgroups were ovariectomized at day 80. An uterotrophic 
assay was performed at day 94: the animals received either 17β-estradiol (E2; 7.8 
µg/kg BW/day in 20 % DMSO/peanut oil) or purely the vehicle (OVX) 
subcutaneously for three days and were then sacrificed.  
 
Fig. 7: Timeline and experimental setting of the study depicting modes of isoflavone (ISO) exposure (in 
utero, lactational, and dietary). A Intact animals received an ISO-free diet (IDD), an ISO-rich diet (IRD) 
or an IDD supplemented with Genistein (GRD). The small intestine was analysed at postnatal day 
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(PND) 25, 50, and 80. B Animals received an IDD, IRD, or GRD were ovariectomized on PND 80 and 
were treated with E2, or the vehicle from PND 94 up to PND 97. 
 
Diets 
The rats had free access to one of three diets: an ISO-free diet (IDD; SSniff R/M-H, 
Ssniff GmbH, Soest, Germany), an ISO-rich diet (IRD; Harlan Teklad 8604 rodent 
diet, Harlan Winkelmann, Borchen, Germany), or an IDD supplemented with 700 µg 
GEN (GRD; 4´,5,7-trihydroxyisoflavone, LC Laboratories, Woburn, USA) per g diet. 
The IRD contains 248 µg GEN/g, 213 µg DAI/g and 59 µg glycitein/g diet (each 
calculated as aglykone). 
 
Tissue preparation 
Body weights of animals were determined. Afterwards, animals were decapitated 
and blood was collected. The small intestine and the uterus were removed and the 
uterus was weighted. Specimen of each was either snap frozen in liquid nitrogen for 
mRNA and protein preparation. 
 
RNA preparation 
Frozen tissue specimen of the intestine was powdered and homogenized in 
TRIzol®. Total RNA was isolated from cells using the TRIzol® (Invitrogen Life 
Technologies, Karlsruhe, Germany) standard protocol (Chomczynski & Sacchi, 
1987) followed by cDNA synthesis with the Quantitect® Reverse Transcription Kit 
(Quiagen, Hilden, Germany). 
 
Real-time RT PCR 
To determine the mRNA expression of ERα, ERβ, p63, PCNA and PS2 quantitative 
real-time RT-PCR was performed in the MxPRO (Stratagene) with Platinum® Taq 
DNA Polymerase (Invitrogen, Karlsruhe, Germany). SybrGreen I® was used as 
detection dye. As housekeeping gene served the Cytochrome-C-oxidase subunit 1A 
(1A), and the expression of all genes was normalized to 1A. Specific primers were 
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designed with the primer3 software (Whitehead Institute for Biomedical Research, 
Cambridge, USA) based on the cDNA sequences available at the EMBL database: 
1A: up: 5’-CGTCACAGCCCATGCATTCG-3 ‘, dw: 5’-
CTGTTCATCCTGTTCCAGCTC-3 ‘; PS2: up: 5´-GGAAAGGGTTGCTGTTTTG-3´, 
dw: 5´-ACAGGTGTGTATGAAGCAGGTG-3´; ERα: up: 5´-
GGAAGCACAAGCGTCAGAGAGAT-3´, dw: 5´-AGACCAGACCAATCATCAGGAT-
3´; ERβ: up: 5´-CTACAGAGAGATGGTCAAAAGTGGA-3´, dw: 5´-
GGGCAAGGAGACAGA AAGTAAGT-3´; P63: up: 5’-
ATCGTTACTCTGGAAACCAG-3’, dw: 5’- CATGTGAGTGCCCATCATAG-3’. The 
PCR program consisted of a first denaturation step at 95°C for 4 min, followed by 45 
cycles of 30 sec at 94°C, 30 sec at 60°C and 30 sec at 72°C. The fluorescence was 
quantified during the 72°C elongation step and the product formation was confirmed 
by melting curve analysis (55–95°C). For calculation of relative rates of gene 
expression the ∆∆CT method was used (Pfaffl, 2001). Gene expressions were 
compared to those of control animals fed with the ISO-free diet.  
 
Statistical analysis 
Statistical analysis was performed using the SPSS Statistical Analysis System, SAS, 
Version 12.0. All data are expressed as arithmetic means with standard deviations. 
First a global Kruskal-Wallis-H-Test was performed to analyse if there are significant 
differences between the groups. In case of differences, additionally a Mann-
Whitney-U-Test was performed. At PND 25, 50, and 80 the nutrition groups were 
compared to each other, and E2 were compared to OVX. Statistical significance was 
established at p < 0.05. 
  
 45 
 
Results 
The experimental setting of the study is depicted in Figure 7. ISO Serum 
concentrations were measured as reported before (Molzberger et al., 2012). 
Consumption of an IDD revealed no detectable serum concentrations of ISO, 
whereas an IRD resulted in 1.1 µM GEN and 2 µM DAI. After GRD 2.5 µM GEN was 
measured in the serum, whereas no DAI was detectable. 
To investigate the effects of the diets on estrogen mediated signaling pathways, we 
determined the ERα and ERβ mRNA expression at PND 25, 50 and 80. No 
significant differences in the gene expression of the ERα (Fig. 8 A) could be 
observed.  
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Fig. 8: mRNA Expression of ERα (A), ERβ (B), and p63 (C) in the small intestine of 25, 50, or 80 days 
old female wistar rats. IDD served as control and were set to one. The bars shown are mean +SD. Six 
rats were included to each group. * = sign. vs. IDD (p < 0.05); + = sign. vs. IRD (p < 0.05); (Kruskal-
Wallis H-Test followed by a Mann-Whitney U-Test) 
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The mRNA expression of ERβ (Fig. 8 B) was significantly decreased in GRD 
animals compared with all ages. As an additionally molecular marker we also 
studied the gene expression of the oncogene transformation related protein p63 in 
the small intestine, which were not affected by the diets (Fig. 8 C). 
To evaluate the influence of lifelong exposure to ISO on tissue homeostasis of the 
small intestine, the gene expression of PCNA and PS2 were determined in 25, 50 
and 80 days old intact female rats (Fig. 9). The mRNA expression of PCNA was 
significantly down-regulated in IRD and GRD animals at PND 25 but significantly 
increased at PND 50 and 80 (Fig. 9 A). The expression of PS2, a gene believed to 
be involved in mucosal repair, was significantly increased at day 25 in the IRD but 
not in the IDD and GRD group (Fig. 9 B). At PND 50 and 80, the PS2 gene 
expression was significant higher in IRD and GRD animals compared to IDD. 
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Fig. 9: mRNA Expression of PCNA (A) and PS2 (B) in the small intestine of 25, 50, or 80 days old 
female wistar rats. IDD served as control and were set to one. The bars shown are mean +SD. Six rats 
were included to each group. * = sign. vs. IDD (p < 0.05); + = sign. vs. IRD (p < 0.05); (Kruskal-Wallis 
H-Test followed by a Mann-Whitney U-Test) 
 
After ovariectomie, we investigated the effect of a lifelong exposure to different diets 
on the E2 sensitivity of the small intestine. As molecular markers, the gene 
expression of ERα, ERβ, p63, PCNA and PS2 were determined. The ERα mRNA 
expression (Fig. 10 A) was significantly reduced in OVX IRD and GRD compared to 
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group, whereas in the IRD and GRD group the mRNA expression of ERα and ERβ 
was reduced (Fig. 10 B). Additionally, the mRNA expression of p63 was reduced in 
OVX animals of the IRD and GRD group compared to IDD animals. After treatment 
with E2, a significant decrease could be measured in all dietary groups (Fig. 10 C).  
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Fig. 10: mRNA Expression of ERα (A), ERβ (B), and p63 (C) in the small intestine of ovariectomized 
wistar rats after treatment with E2 or the vehicle (OVX). IDD OVX served as control and were set to 
one. The bars shown are mean +SD. Six rats were included to each group. * = sign. vs. IDD OVX (p < 
0.05); + = sign. vs. IRD OVX (p < 0.05); # = sign. vs. IDD E2 (p < 0.05); † = sign. vs. IRD E2 (p < 0.05); 
(Kruskal-Wallis H-Test followed by a Mann-Whitney U-Test) 
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No differences in the PCNA expression in the small intestine could be observed 
between OVX animals of the respective nutrition groups, and also treatment with E2 
had no effect (Fig. 11 A). The PS2 expression (Fig. 11 B) was significantly 
decreased in OVX IRD animals but significantly increased in OVX GRD animals 
compared to the IDD group. Treatment with E2 resulted in a significant down-
regulation of PS2 in all dietary groups, with the lowest expression in IRD animals. 
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Fig. 11: mRNA Expression of PCNA (A) and PS2 (B) in the small intestine of ovariectomized wistar 
rats after treatment with E2 or the vehicle (OVX). IDD OVX served as control and were set to one. The 
bars shown are mean +SD. Six rats were included to each group. * = sign. vs. IDD OVX (p < 0.05); + = 
sign. vs. IRD OVX (p < 0.05); # = sign. vs. IDD E2 (p < 0.05); † = sign. vs. IRD E2 (p < 0.05); (Kruskal-
Wallis H-Test followed by a Mann-Whitney U-Test) 
 
  
A B 
* 
* 
* 
# 
+ 
* 
* 
 49 
 
Discussion 
The ERβ is the predominantly expressed ER in the intestine, and it is known to 
affect the homeostasis of this tissue (Weige et al., 2009). In studies with ERβKO 
mice it was shown that the ERβ is essential for maintenance of tissue homeostasis. 
In a study of our group an ERβ-specific agonist and GEN were able to inhibit 
proliferation and to induce apoptosis in the large and small intestine of 
ovariectomized rats (Schleipen et al., 2011). This observation indicates that the 
activation of ERβ results in a modulation of homeostasis of intestine tissue which 
again may result in protection from tumor development. 
Analysis within our study of the ERα expression at different PND showed no 
significant differences between the nutrition groups (Fig. 8 A). Here it has to be 
stated that in the intestine the expression of ERα is generally low, and did not differ 
between normal and malign intestinal cells (Campbell-Thompson et al., 2001; 
Konstantinopoulos et al., 2003).  
In Figure 8 B it is clearly visible that GRD significantly reduced the expression of 
ERβ at PND 25, 50 and 80 but is not affected in the IDD and IRD group. The 
observed down regulation of ERβ mRNA expression may be due to the higher 
serum concentrations of GEN in the animals of the GRD group compared to IDD 
and IRD. This assumption is based on the knowledge that binding of a ligand to the 
ERβ results in a reduced ERβ mRNA expression and that GEN binds with high 
preference to ERβ (Barkhem et al., 1998; Wood et al., 2006).  
In our study at PND 25, 50 and 80 no significant differences in p63 expression could 
be detected. P63 is a homologue of p53, and is overexpressed in human tumors 
(Flores et al., 2005). A previous study of our laboratory showed that p63 expression 
decreases in response to GEN and the ERβ-specific ligand (Schleipen et al., 2011). 
It seems to play an important role in regulating epithelial proliferation and 
differentiation, and to be involved in tumorigenesis. P63 is able to bind to the ligand 
binding domain of the ER (Littlewood et al., 1995; Caserta et al., 2006; Nguyen et 
al., 2006). We hypothesized that expression of p63 is decreased after lifelong 
exposure to ISO or GEN solely, but no differences could be measured in its 
expression level. 
As shown in Figure 9 A the proliferative activity, indicated by the expression of the 
proliferating cell nuclear antigen (PCNA), was significantly lower compared to the 
IRD and GRD groups at day 25, but increased at PND 50 and PND 80. The reduced 
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expression of PCNA at day 25 is in line with observations in piglets (Chen et al., 
2005) demonstrating that treatment with GEN (5 mg GEN/kg BW/day) for 10 days 
resulted in inhibition of proliferation. It is assumed that activation of the ERβ is 
responsible for this inhibitory effect (Helguero et al., 2005; Martineti et al., 2005). 
Our observation that proliferation is increased at day 50 and 80 could be due to the 
fact that ISO act as estrogenic compounds in the presence of low estrogen 
concentrations, whereas at higher estrogen levels they act anti-estrogenic (Hwang 
et al., 2006). In line with this assumption PCNA expression was reduced at PND 25, 
because at this age the hormone concentrations are expected to be low. After 
gaining puberty around PND 35 the ovaries produce estrogens and therefore the 
ISO may act as anti-estrogens and so the PCNA expression raise at PND 50 and 
80. This hypothesis is supported by a study with ovariectomized rats with low 
estrogenic background where the expression of PCNA is reduced after three weeks 
treatment with GEN (Schleipen et al., 2011). 
The PS2 gene is described to have an important role in regenerating tissue during 
wound healing in inflammatory bowel diseases and stimulation of mucosal repair 
(Playford et al., 1996; Ribieras et al., 1998). PS2 is regulated by estrogens via 
transcriptional mechanisms (Berry et al., 1989). In our study IRD and GRD increase 
PS2 expression at PND 25, 50 and 80 (Fig. 9 B). This observation confirms a 
previous study in premenopausal women where supplementation with dietary soy 
(45 mg ISO/d) for two weeks resulted in an increased expression of PS2 in the 
breast (Hargreaves et al., 1999). We see two possible szenarios explaining our 
results that the exposure to ISO results in an increase of PS2 expression. On the 
one hand, a high nutritive GEN intake could lead to intestinal damage, and therefore 
the PS2 expression rose to induce wound healing and the proliferation increased 
resulting from regenerating cells. On the other hand, it could be an indication for an 
increased resistance to intestinal damage and protection against malignant 
transformation. The latter would follow the findings that loss of PS2 may occur as an 
early event in the malignant transformation process of intestinal-type tumors (Wu et 
al., 1998).  
In Figure 10 A and B it is demonstrated that lifelong exposure to ISO also affects the 
response of ERα and ERβ towards E2 treatment. Although the binding affinity of ISO 
is lower to the ERα than to the ERβ ISO are able to reduce the ERα expression. As 
the mRNA expression of the ER is down-regulated in response to binding of a 
ligand, it can be assumed that binding of ISO is what reduces ERα. Furthermore, 
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mRNA expression of ERβ is lower in the GRD than in the IRD group indicating a 
higher estrogenic potency of GEN solely. 
The expression of p63 was strongly effected as well by the diets and E2 (Fig. 10 C). 
It is clearly visible that IRD and GRD resulted in a decreased p63 expression in the 
intestine. The fact that treatment with E2 resulted in a down regulation of p63 also in 
the IDD group and further reduced the p63 expression in IRD and GRD animals, is 
in line with recent observations demonstrating that treatment with ERβ-specific 
agonists led to significant down-regulation of p63 expression (Schleipen et al., 
2011). 
Like shown in Figure 11 in this experimental design independent of the diet, 
administration of E2 does not affect intestinal proliferation (Fig. 11 A). PS2 displays a 
nutrition dependent E2 response in OVX animals. In our study the PS2 expression 
was highest in OVX rats who received a GRD throughout life which could be taken 
as an indicating for a tumor protective effect of GEN in this tissue (Fig. 11 B). A 
previous study from our laboratory points out that E2 decreases the expression of 
PS2 in the intestine of female rats (Hofer et al., 2010), which is confirmed by our 
own findings. E2 treatment resulted in a significant reduction of PS2 in all nutrition 
groups. Additionally, these results are supported by a study with postmenopausal 
macaques where the PS2 expression is down-regulated at high doses of ISO (509 
mg ISO (GEN + DAI) per day) in a high estrogenic environment (Wood et al., 2006). 
On the opposite, treatment with HRT over 3 months resulted in a rise of PS2 
expression in the postmenopausal female breast (Harding et al., 2000). However, as 
the intestine does not belong to the classical estrogen sensitive tissues, it can be 
assumed that the treatment period of three days was too short to induce estrogenic 
actions. 
Same argumentation can be applied to the PCNA expression of our study. Only a 
tendency of reduced proliferation could be observed possible due to the short 
treatment period regarding the inhibition of proliferation showed in the study of 
Schleipen (Schleipen et al., 2011), while a lot of studies showed a protective effect 
of HRT against developing cancer in the intestine (Nelson et al., 2002). The reduced 
expression of PS2 leads to the suggestion that on the one hand the protection 
against intestinal damage were lost after E2 treatment. On the other hand, E2 
treatment could result in a decrease of intestinal damage. This is underlined by the 
reduced expression of p63 in these groups, indicating a reduced risk of developing 
cancer. 
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In summary our results provide evidence that a lifelong exposure to an ISO-rich diet 
may improve intestine homeostasis, and modulate the expression of molecular 
markers related to tumor protection and the responsiveness of this tissue towards 
E2. Consequently, this may affect the susceptibility of this tissue to develop cancer. 
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CHAPTER FOUR 
 
Pre- to post-pubertal exposure to isoflavones modulates the sensitivity of the 
mammary gland towards estrogens in female rats 
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Abstract: 
The aim of this study was to identify critical periods during development responsible 
for the tissue specific alterations of estradiol (E2) sensitivity induced by isoflavones 
(ISO). Female rats were divided into three nutrition groups: first group received an 
ISO-free diet (IDD) throughout life, second group an ISO-containing diet (ISD) 
throughout life, and a third group was exposed to an ISD from postnatal day (PND) 
30 to PND 60 which cover the time period shortly before onset of puberty up to end 
of puberty (pISD). The onset of puberty was ascertained, the menstrual cycle length 
was measured and from each nutrition group one subset of animals was sacrificed 
during puberty (PND 50) and during adulthood (PND 80). Onset of puberty occurred 
significantly earlier in pISD and ISD compared to IDD. Menstrual cycle length was 
shortest in pISD. While proliferative activity and PR expression in the mammary 
gland was not affected by IDD and ISD, a significant increase could be detected in 
pISD animals at PND 50. Rats were ovariectomized and subcutaneously treated 
either with E2, GEN, or the vehicle (OVX), for three days (PND 77–80) to determine 
estrogen sensitivity. Analysis of Ki-67 and PCNA showed a reduced proliferative 
response to E2 in pISD and ISD compared to IDD, while the induction of PR was 
higher in both IDD and pISD compared to ISD. Our results indicate a reduction of 
the proliferative response of the mammary gland towards estrogens due to ISO 
exposure solely during PND 30 and 60, while this timeframe seems too late to 
influence estrogen sensitivity.   
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Introduction: 
There is increasing evidence that the reduced breast cancer risk in eastern Asian 
countries compared to Europe and the USA is related to high soy consumption 
(Ursin et al., 1994; Adlercreutz, 2002; Cassidy, 2003; Badger et al., 2005; 
Nichenametla et al., 2006; Usui, 2006). Soy is the main source of isoflavones (ISO), 
which are polyphenolic non-steroidal compounds. After ingestion, an initial 
hydrolysis of the sugar moiety of the glycosides seems to be required for absorption, 
which is catalysed by the brush border glucosidase in the small intestine or by 
bacterial β-glucosidases or β-glucuronidases in the colon (Setchell et al., 2002; 
Mortensen et al., 2009). The enterobacteria metabolize daidzein (DAI) to 
dihydrodaidzein (DH-DAI), which can be further converted to equol or O-
desmethylangolensin (Key et al., 1999). Genistein (GEN) is reduced to 
dihydrogenistein (DH-GEN) by the gut microbiota as well, and is further metabolized 
to 6´-hydroxy-O-desmethylangolensin (6´-OH-ODMA). The gut microbiota is 
essential for the metabolism of ISO, and its composition is influenced by 
physiological, pathological and environmental factors, but also by gender, genetics, 
and ethnicity (Mortensen et al., 2009).  
Because of their structural similarity to endogenous estrogens, ISO are able to bind 
to the estrogen receptor α (ERα) and β (ERβ). Both receptor subtypes can be found 
in the mammary gland. Albeit the expression of the ERα is generally low in normal 
mammary gland, it increases in proliferative benign tissue (Roger et al., 2000). The 
content of ERα in the breast is proportional to the rate of proliferation, and the co-
expression of ER and the proliferation marker Ki-67 is described as the 
manifestation of an important early molecular change in the development of cancer 
(Shoker et al., 1999). 
One function of the ERβ seems to be the counteraction of ERα (Saji et al., 2005; 
Chang et al., 2006). There is evidence that activation of the ERβ reduces the 
estrogen stimulated proliferation in MCF-7 and T47D breast cancer cells (Omoto et 
al., 2003; Strom et al., 2004). As the binding affinity of ISO is 30-times higher to ERβ 
than to ERα it seems reasonable to assume that ISO are able to protect from 
developing breast cancer via activating ERβ. Still, the effects of ISO are discussed 
controversially. Studies in breast cancer cells and animal cancer models described a 
higher growth of the tumor in response to treatment with ISO (Wang et al., 1996; Ju 
et al., 2006).  
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The controversial discussion might be resolved when taking the timing of the ISO 
exposure into account. Numerous studies have shown that ISO intake has to start 
pre-pubertal to exert protective effects. There is evidence that ISO may influence the 
development of the mammary gland, and therefore it seems to be reasonable that 
ingestion of ISO has to start before pubertal changing of the breast occurs (Cabanes 
et al., 2004; Padilla-Banks et al., 2006). Morphological alterations of the mammary 
gland are one factor of influencing breast cancer risk. Further risk factors for 
developing breast cancer is the extent of lifelong estrogen exposition implicating 
early onset of menarche, late onset of menopause, high levels of free circulating 
estrogens, and short menstrual cycle length (Toniolo et al., 1995; Lu et al., 1996; 
Hulka & Moorman, 2001). The critical role for estrogens in the development of 
breast cancer is under investigation for over thirty years (Noble & Cutts, 1959; Wotiz 
et al., 1978; Cavalieri & Rogan, 2006; Yager & Davidson, 2006; Santen et al., 2009). 
Elevated levels of endogenous estradiol in postmenopausal women have been 
found to increase the risk of developing breast cancer. Additionally, a recently 
performed meta-analysis found a positive association between premenopausal 
estrogen concentrations and breast cancer risk (Walker et al., 2011). 
A previous study from our laboratory showed a significant decrease in estrogen 
sensitivity of the mammary gland after lifelong exposure to an ISO-rich diet or GEN-
rich diet (Molzberger et al., 2012). In that study, the exposure to ISO started already 
in utero, but there is evidence that ISO exposure starting pre-pubertal is sufficient to 
exert protective effects towards developing breast cancer (Lee et al., 2009). To 
evaluate the relevance of the time of ISO exposure, we designed this further animal 
experiment, where lifelong exposure to an ISD is compared to an ISD starting just 
before puberty onset up to adulthood from postnattally day (PND) 30 to PND 60. 
Within the experiment puberty onset and menstrual cycle length were determined 
and the expression of Ki-67, PCNA, and PR was measured. 
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Materials and Methods: 
Diets 
The animals had free access to one of two diets containing different amount of ISO: 
an ISO-free diet (IDD; Sniff RM/H phytoestrogenfree, Ssniff GmbH, Soest, 
Germany), or an ISO-containing diet (ISD; Sniff RM/H, Ssniff GmbH, Soest, 
Germany). The ISO content of the diets are depicted in Tab. 5. 
 
Experimental animals and study design 
All animal handling and experimental conditions were carried out according to the 
“Institutional Animal Care and Use Committee guidelines”, regulated by the German 
federal law for animal welfare. 
Wistar rats were obtained from Janvier (Le Genest St Isle, France) and kept under 
controlled conditions of temperature (20°C ± 1), relative humidity (50–80 %) and 
illumination (12 h dark, 12 h light). The female rats were mated and the dams were 
fed one of the two diets during pregnancy and nursing (IDD: n = 14, ISD: n = 7). 
After weaning the female offspring were divided into three dietary groups (n = 30 
each dietary group) and had ad libitum access to the diets and water.  
The first dietary group received an IDD throughout life (IDD). The second received 
an ISD for part of their life (pISD) before onset of puberty up to young adulthood 
from postnatal day (PND) 30 to 60. The third dietary group received an ISD 
throughout life (ISD). Each dietary group was further divided into five subgroups (n = 
6 each group). The first subgroup of each dietary group was sacrificed in their 
puberty life period on postnatal day 50 (puberty), the second in the adult phase of 
life on PND 80. The other three subgroups were ovariectomized (PND 60) and an 
uterotrophic assay was performed at day 77. The animals received 17β-estradiol 
(E2; 4 µg/kg BW/day), genistein (GEN; 100 mg/kg BW/day), or purely the vehicle 
(OVX) subcutaneously for three days and were afterwards sacrificed. The 
estrogenic compounds were solved in 20 % DMSO/peanut oil. 
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Fig. 12: Timeline and experimental setting of the study. A Intact animals received either lifelong and 
IDD or ISD, or an ISD starting pre-pubertal up to the end of puberty (PND 30–PND 60, pISD). B 
Animals received an IDD, pISD or ISD were ovariectomized on PND 60 and were treated with E2, 
GEN, or the vehicle from PND 77 up to PND 80. Afterwards, these animals were sacrified and the 
proliferation and the estrogenic response of the mammary gland were determined 
 
Quantification of ISO derivatives in the diet by HPLC/DAD analysis 
The pelleted diet ISD was crushed using mortar and pestle. Approx. 250 mg of an 
accurately weighted sample of each homogenized diet powder were vortexed for 30 
s in exactly 40 mL 65 % (v/v) methanol and extracted gently for 60 min at room 
temperature using an overhead rotation shaker. The suspensions were centrifuged 
at 8600 g for 5 min and filtered using 15 mm 0.45 um PTFE syringe filters. The 
filtrate was diluted by pipetting 1 ml of the solution into a 50 ml graduated flask and 
make up to the mark with 65 % (v/v) methanol.  
The LC-DAD analyses were performed on a Shimadzu LC system equipped with a 
controller (CBM-20A), a degasser (DGU-20A3), two pumps (LC-20AD), an 
autosampler (SIL-20AC HT), a column oven (CTO-20AC) and a diode array detector 
(SPD-M20A). The LC system was controlled by the software LC solution 1.24. 
Separation of the ISO derivatives was performed on a Phenomenex Kinetex PFP 
column (3.0 mm internal diameter, 100 mm length, 2.6 µm) with an oven 
temperature of 35°C. Solvent A was 0.1 % (v/v) formic acid in bidest. water and 
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solvent B was acetonitrile (LC grade). Flow rate was 0.7 mL/min, the injection 
volume 10 µL. The LC gradient started with an initial period of 3 min at 10 % B, 
increasing linearly to 45 % B at 12 min, and finally to 100 % at 12.5–15.5 min, re-
equilibrating the system in a 7.5 min postrun (10 % B). Eluent was monitored 
between 200 and 500 nm using diode array detection. Peaks were integrated at 250 
nm. The identity of each compound was confirmed by the retention time and the UV-
Vis spectra. The limit of quantification (LOQ) and lowest calibration point was 0.8 
nmol for all target analytes. 
 
Chemicals used for measurement of ISO-metabolites in the blood serum 
DAI, GEN and glycitein were purchased from LC Laboratories (Woburn, MA, USA). 
Daidzin, genistin, glycitin, 6''-O-acetyl-daidzin, 6''-O-acetyl-genistin, 6''-O-acetyl-
glycitin, 6''-O-malonyl-daidzin, 6''-O-malonyl-genistin and 6''-O-malonyl-glycitin were 
purchased from Wako (Neuss, Germany). DH-DAI was purchased from Toronto 
Research Chemicals (North York, Canada). DH-GEN and equol were purchased 
from APIN Chemicals LTD (Abingdon, UK). ODMA and 6'-OH-ODMA were 
purchased from Plantech UK (Reading, UK). [3,4,8-13C3]daidzein was provided by 
Nigel Botting (University of St. Andrews, UK). 
 
Measurement of ISO-metabolites in the blood serum 
Rat serum samples (90 µl) were thawed and 5 µl of internal standard (2 µM [3,4,8-
13C3]daidzein stock solution in DMSO) was added. 500 µl of an ammonium acetate 
buffer (0.1 M, pH 5.0) containing 1,4-dithiothreitol (100 mM), 1200 U β-
glucuronidase (bovine liver, Typ B-3) and 120 U arylsulfatase (Helix pomatia, Typ H-
1) was added, and the mixture was incubated for 2 h at 37°C. The sample was 
acidified with 1200 µl of 50 mM H3PO4 solution (ice-cooled) and purified via SPE 
extraction. Therefore the SPE cartridges (Strata-X AW, 60 mg, 3 ml, Phenomenex, 
Torrance, USA) were conditioned with 2 ml of methanol and equilibrated with 2 ml of 
water. After loading with the sample solutions the cartridges were first washed with 2 
ml of 2 % (v/v) formic acid solution. The second wash step was performed with 2 ml 
of 50 % (v/v) methanolic solution. The analytes were eluted with 1 ml of 2 % (v/v) 
ammonia (25 %) in methanol and evaporated to dryness under a nitrogen stream. 
The residues were redissolved in 100 µl of 30 % (v/v) methanolic solution and an 
aliquot of each sample was analysed by LC/MS as described below. For calibration 
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blank plasma was worked up as described above and analytes were added before 
analysis in an end concentration range between 5 and 10,000 nM.  
The modest recovery rate of 6’-OH-ODMA was acceptable because of the fact that 
the measured levels of this metabolite were very low, and therefore not of biological 
significance. 
The HPLC-MS analyses were performed on an ABSciex QTrap 5500 mass 
spectrometer equipped with a Shimadzu LC system, which consisted of a controller 
(CBM-20A), a degasser (DGU-20A5), two pumps (LC-30AD), an autosampler (SIL-
30AC) and a column oven (CTO-20AC). The LC-MS system was controlled by the 
software Analyst 1.5.2. The Turbo Spray ESI Source was operated in the negative 
mode. The source parameters were as follows: Curtain gas (CUR) 40 psi, ion spray 
voltage (IS) -4500 V, ion source gas-1 (GS 1) 80 psi, ion source gas-2 (GS 2) 70 
psi, ion source gas-2 temperature (TEM) 600°C. Two multi-reaction monitoring 
(MRM) transitions (a quantifier and a qualifier ion transition for each compound) 
were used.  
Separation of the analytes was performed on a Waters Acquity HSS T3 (2.1 mm 
internal diameter, 100 mm length, 1.8 µm) with an oven temperature of 40°C. 
Solvent A was a 20 mM ammonium formate buffer (pH 3) and solvent B was an 
acetonitrile/methanol mixture (1 / 2.5, v/v) (LC grade). Flow rate was 0.5 ml/min, the 
injection volume 10 µl. The elution profile was as follows: 0–2.6 min isocratic with 3 
% B, 2.6–16.7 min from 3 % to 56 % B, 16.7–17.3 min from 56 % to 95 % B, 17.3–
19.9 min isocratic with 95 % B, 19.9–20.5 min from 95 % to 3 % B and 20.5–24.7 
min isocratic with initial conditions. The limits of quantification (LOQ) for each 
analyte in serum were as follows: 50 fmol for DAI, GEN, DH-DAI, DH-GEN, ODMA 
and 6’-OH-ODMA. The LOQ for equol was 1 pmol. We defined the limit of detection 
(LOD) as one third of the respective LOQ. 
 
Determining puberty onset and menstrual cycle length 
To investigate the puberty onset the day of vaginal opening was determined. 
Additionally, menstrual cycle length was measured. Therefore a vaginal smear test 
was performed daily for one week starting the day after puberty onset. 
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Tissue preparation 
Animals were decapitated after weighing and blood was collected. The mammary 
gland and the uterus were removed and the uteri were weighed. Specimen of each 
was snap frozen in liquid nitrogen for mRNA preparation. 
 
RNA preparation 
Frozen mammary gland tissues were powdered, pooled and homogenized in 
TRIzol®. Total RNA was isolated from cells using the TRIzol® (Invitrogen Life 
Technologies, Karlsruhe, Germany) standard protocol (Chomczynski & Sacchi, 
1987) followed by cDNA synthesis with the Quantitect® Reverse Transcription Kit 
(Quiagen, Hilden, Germany). 
 
Real-time RT-PCR 
To determine the mRNA expression of Ki-67, PCNA and PR quantitative real-time 
RT-PCR was performed in the MxPRO (Stratagene) with Platinum® Taq DNA 
Polymerase (Invitrogen, Karlsruhe, Germany). SybrGreen I® was used as detection 
dye. The Cytochrome-C-oxidase subunit 1A (1A) was used as housekeeping gene, 
and the expression of all genes were normalized to 1A. Specific primers were 
designed with the primer3 software (Whitehead Institute for Biomedical Research, 
Cambridge, USA) based on the cDNA sequences available at the EMBL database: 
1A: up: 5’-CGTCACAGCCCATGCATTCG-3 ‘, dw: 5’-
CTGTTCATCCTGTTCCAGCTC-3 ‘; PR: up: 5’-CATGTCAGTGGACAGATGCT-3’ ‘, 
dw. 5’-ACTTCAGACATCATTTCCGG-3 ‘; PCNA: up: 
5´GAGCAACTTGGAATCCCAGAACAGG-3´,dw: 5´ 
CCAAGCTCCCCACTCGCAGAAAACT-3´; Ki-67: up: 5´-
AACCAGGACTTTGTGCTCTGTAA-3´, dw: 5´-CTCTTTTGGCTTCCATTTCTTC-3´. 
The PCR program consisted of a first a denaturation step at 95°C for 4 min, followed 
by 45 cycles of 30 sec at 94°C, 30 sec at 60°C and 30 sec at 72°C. The 
fluorescence was quantified during the 72°C elongation step and the product 
formation was confirmed by melting curve analysis (55–95°C). For calculation of 
relative rates of gene expression the ∆∆CT method was used (Pfaffl, 2001). Gene 
expressions are shown in relation to control animals fed with the ISO-free diet.  
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Statistical analysis 
Statistical analysis was performed using the SPSS Statistical Analysis System, SAS, 
Version 12.0. All data are expressed as arithmetic means with their standard 
deviations. First a global Kruskal-Wallis-H-Test was performed to analyse if there 
are significant differences between the groups. In case of differences, a Mann-
Whitney-U-Test was additionally performed to identify the groups with statistical 
significant variance. At PND 50 and 80 nutrition groups were compared to each 
other, and the different treatment groups were compared to the OVX control groups. 
Statistical significance was established at p < 0.05. 
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Results: 
The experimental design of this study is depicted in Fig. 12. The IDD contains no 
detectable amounts of ISO (< 10 µg/g). The ISD contains 113.54 µg GEN/g, 147.41 
µg DAI/g and 36.06 µg GLY/g (each calculated as aglycone) as depicted in Table 5. 
Food intake was monitored during the study but no significant differences could be 
shown between the nutrition groups (data not shown). 
 
 
ISO derivative  MW  mean value mean value calculated  
[g/mol] µg/g ISD µM/g ISD as aglyc. 
Daidzein   254.24  11.54  0.045  11.54 
Genistein   270.24  12.91  0.048  12.91 
Glycitein   284.27  1.66  0.006  1.66 
Daidzin   416.38  86.22  0.207  52.65 
Genistin   432.38  104.84  0.242  65.52 
Glycitin   446.4  33.38  0.075  21.26 
6''-O-Acetyl-Daidzin  458.41  19.83  0.043  11.00 
6''-O-Acetyl-Genistin  474.41  20.63  0.043  11.75 
6''-O-Acetyl-Glycitin  488.44  5.36  0.011  3.12 
6''-O-Malonyl-Daidzin  502.42  75.79  0.151  38.35 
6''-O-Malonyl-Genistin 518.42  109.78  0.218  57.23 
6''-O-Malonyl-Glycitin  532.45  18.76  0.035  10.02 
Sum of daidzein derivatives calculated as daidzein aglycone in µg/g ISD 113.54 
Sum of genistein derivatives calculated as genistein aglycone in µg/g ISD 147.41 
Sum of glycitein derivatives calculated as glycitein aglycone in µg/g ISD 36.06 
 
Tab. 5: Content of ISO derivatives in the ISO-standard diet (ISD). 
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In Table 6, body weights and uterus wet weights are listed. No significant influence 
could be observed in subject to nutrition or treatment related to body weights, 
whereas treatment with E2 led to a significant increase in uterus wet weights in all 
nutrition groups compared with their OVX groups. Treatment with GEN had no 
significant effect on uterus wet weights in any group. 
 
Body W.  Uterus   
(g)   (mg/kg BW)   
PND 50  IDD   194 ± 2  1986 ± 277   
pISD   182 ± 3  1348 ± 99   
ISD   195 ± 9  1300 ± 237   
PND 80 IDD   265 ± 4  982 ± 76   
  pISD   260 ± 9  1548 ± 176   
ISD   245 ± 8  1124 ± 100   
OVX   IDD   300 ± 7  266 ± 13   
pISD   301 ± 12  259 ± 19   
ISD   328 ± 14  273 ± 24   
E2  IDD   286 ± 6  1170 ± 98**  
  pISD   269 ± 8++  1264 ± 103**++  
  ISD   301 ± 5++  1464 ± 175**##  
GEN  IDD   297 ± 9  343 ± 16**  
  pISD   268 ± 7++  380 ± 30**++  
  ISD   324 ± 9++  340 ± 24*  
 
Tab. 6: Body weights (g) and uterus wet weights (mg/kg BW). ** p < 0.01 vs. IDD OVX; ++ p < 0.01 vs. 
pISD OVX; ## p < 0.01 vs. ISD OVX; (Kruskal-Wallis H-Test followed by a Mann-Whitney U-Test) 
 
Table 7 shows the concentrations of DAI, GEN and the metabolites DH-DAI, DH-
GEN, ODMA, 6´-OH-ODMA and equol in the blood serum of 50 (PND 50) and 80 
(PND 80) days old female rats. No ISO-metabolites could be detected in IDD 
animals at PND 50 and 80. Measurement of GEN, DAI and DH-DAI in the blood 
serum revealed significant higher concentrations in the ISD compared to the pISD 
group, whereas no differences were found in case of DH-GEN, ODMA and equol. 
On day 50 and 80, the serum concentrations of GEN, DAI and their metabolites 
were significantly higher after ISD compared to the other diets. 
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DAI  GEN  Equol   DH-DAI DH-GEN ODMA  6´-OH-ODMA 
        
PND 50  IDD n. d.  n. d.  n. d.  n. d.  n. d.  0.009±0.00 n. d.   
pISD 0.044 ± 0.06 0.016±0.03 1.644±0.40** 0.036±0.04** 0.068±0.08** 0.119±0.06** n. d.  
ISD 0.909±0.27**++ 0.901±0.37**++ 2.611±1.10** 0.213±0.10**++ 0.062±0.04* 0.155±0.08** n. d.  
PND 80 IDD 0.011±0.01 n. d.  n. d.   n. d.  n. d.  n. d.  n. d. 
pISD 0.039±0.01 0.005±0.01 n. d.   0.028±0.02 n. d.  0.008±0.00  n. d. 
ISD 0.547±0.28**++ 0.566±0.42**++ 3.039±1.64**++ 0.099±0.06**++ 0.033±0.04*+ 0.190±0.08**++ n. d.  
 
Tab. 7: Serum-concentrations (µM) of DAI, GEN and their metabolites equol, DH-DAI, DH-GEN, ODMA and 6´-OH-ODMA in 50 (PND 50) and 80 (PND 80) days old female 
rats. N. d. = not detectable. * = sign. vs. IDD (p < 0.05); ** = sign. vs. IDD (p < 0.01); + = sign. vs. pISD (p < 0.05); ++ = sign. vs. pISD (p < 0.01); (Kruskal-Wallis H-Test followed 
by a Mann-Whitney U-Test) 
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The influence of pre- to postpubertal and lifelong exposure to ISO on puberty onset 
and menstrual cycle length were determined. It could be shown that ISO exposure 
at any time led to an earlier onset of puberty (Fig. 13 A). Menstrual cycle length was 
shorter in animals where the exposure to ISO started prepubertal compared to those 
who were exposed lifelong or not at all (Fig. 13 B). 
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Fig. 13: A Puberty onset indicated by the day of vaginal opening (postnatal day, PND). B Length of 
menstrual cycle in days. IDD served as control and were set to one. The bars shown are mean +SD. * 
= sign. vs. IDD (p < 0.05); + = sign. vs. pISD (p < 0.05); (Kruskal-Wallis H-Test followed by a Mann-
Whitney U-Test) 
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To evaluate the influence of ISO exposure during different periods of life on the 
proliferation of the mammary gland, the expression of the proliferation markers Ki-67 
and PCNA were analysed. At PND 50, an elevated mRNA expression of Ki-67 and 
PCNA could be measured in pISD and ISD animals compared to IDD, whereas the 
expression in the ISD group were significant lower as in the pISD group (Fig. 14 
A/B). Measurement of Ki-67 and PCNA at PND 80 revealed a significant decrease in 
rats fed an ISD compared to those received and IDD or an pISD. In addition to the 
proliferation markers, the estrogen sensitivity was determined using the 
progesterone receptor (PR). A significant increase in PR mRNA expression could be 
shown in the pISD group at PND 50 and PND 80 (Fig. 14 C). 
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Fig. 14: mRNA expression of PCNA (A), Ki-67 (B) and PR (C) in the mammary gland of 50 (PND 50) 
and 80 (PND 80) days old female Wistar rats. IDD served as control and were set to one. The bars 
shown are mean +SD. Six rats were included to each group. * = sign. vs. IDD (p < 0.05); + = sign. vs. 
pISD (p < 0.05); (Kruskal-Wallis H-Test followed by a Mann-Whitney U-Test) 
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To investigate the influence of ISO exposure during different development stages on 
the estrogen responsivity of the mammary gland, adult female rats were 
ovariectomized and an uterotrophic assay was performed. In mammary gland tissue 
of these rats, proliferation (Ki-67, PCNA) and estrogen sensitivity (PR) were 
determined. No differences in Ki-67 and PCNA mRNA expression could be 
observed in OVX animals. In response to E2 treatment, the proliferation was 
increased in all nutrition groups, whereas pre-exposure to ISO (pISD, ISD) 
significantly diminished the E2 stimulated proliferation (Fig. 15 A/B).  
 
OVX E2 GEN
Fo
ld
 
Ind
uc
tio
n
0
1
2
3
4
5
6
IDD 
pISD 
ISD 
OVX E2 GEN
Fo
ld
 
Ind
uc
tio
n
0
1
2
3
4
IDD 
pISD 
ISD 
 
OVX E2 GEN
Fo
ld
 
Ind
uc
tio
n
0
5
10
15
20
60
80
100
120
140
IDD 
pISD 
ISD 
 
Fig. 15: mRNA expression of PCNA (A), Ki-67 (B) and PR (C) in the mammary gland 80 days old 
female Wistar rats after ovariectomie followed by three days of treatment with the vehicle (OVX), 
estradiol (E2), or genistein (GEN). IDD OVX served as control and were set to one. The bars shown are 
mean +SD. Six rats were included to each group. * = sign. vs. IDD OVX (p < 0.05); + = sign. vs. IDD E2 
(p < 0.05); # = sign. vs. pISD E2 (p < 0.05); (Kruskal-Wallis H-Test followed by a Mann-Whitney U-Test) 
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The progesterone receptor was determined as estrogenic marker on mRNA level 
showing that treatment with E2 resulted in an elevated mRNA expression of PR in all 
groups, whereas IDD and pISD fed animals showed an additional increase 
compared to rats received an ISD (Fig. 15 C).  
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Discussion: 
Our observation that animals receiving ISO either lifelong or during puberty have a 
significant earlier onset of puberty than animals receiving no ISO confirms the 
animal study conducted by the group of Whitten (Whitten & Naftolin, 1992). They 
reported that chronic exposure (PND 22–PND 60) to dietary concentrations (0.1 % 
of the diet) of the phytoestrogen coumestrol led to an accelerated vaginal opening. 
Our results correlates as well with several studies which show that menstrual cycle 
length is elongated in response to ISO exposure (Lu et al., 1996; Kumar et al., 
2002). In our animal experiment, the menstrual cycle length was shortest for animals 
where the ISO exposure started prepubertal. As both puberty onset and menstrual 
cycle length being estrogen sensitive markers, these observations lead to the 
assumption that estrogen sensitivity increases if the ingestion of ISO starts 
prepubertal but not already in utero. 
Uterus wet weights remained unaffected by the different diets indicating a low 
estrogenic potential of the ISD. 
Regarding the ISO serum concentrations on PND 50, significant differences could 
be observed between pISD and ISD, although animals of both groups received the 
same diet at this time. Exposure to ISO starting prepubertal resulted in significant 
lower concentrations of GEN and DAI than lifelong ISO exposure, whereas their 
metabolites show no differences, which could lead to the assumption that ISO 
metabolism is altered in pISD animals. The ISO metabolism depends amongst 
others on enterobacteria (Mortensen et al., 2009). The different ISO content in the 
blood serum could be explained by altered gut microflora in animals receiving ISO 
pre- to postpubertal compared to animals receiving ISO lifelong. The gut microflora 
begins to develop within a week of birth and continues to change from infancy into 
adulthood. As it is known that ISO are able to cross the placenta and that they occur 
to a little extent in mothers milk, it could be assumed that animals where the 
exposure started in utero developed a different gut microflora compared to animals 
where ISO exposure started prepubertal. These differences in enterobacteria could 
be responsible for the altered metabolism of ISO in pISD compared to ISD animals. 
In a previous experiment of our group proliferation of the mammary gland was 
elevated after lifelong exposure to ISO or GEN solely at PND 50 (Molzberger et al., 
2012). This observation is confirmed by the results of the present study where pISD 
and ISD led to an increase of proliferation on PND 50 (Fig. 14 A/B). A possible 
explanation for this effect is a change in the differentiation of the mammary gland in 
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response to ISO. This explanation goes hand in hand with observations by Fritz et 
al. who showed that early exposure (GD 0–PND 21) to physiological doses of the 
ISO GEN (0, 25, 250 mg/kg diet) via diet induces cell differentiation. This 
reprogramming of the mammary gland resulted in a reduced susceptibility of this 
tissue to develop cancer (Fritz et al., 1998). 
To investigate whether the ISO exposure during different periods of life influences 
the estrogen responsivity of the mammary an uterotrophic assay was performed. 
This assay served as a model system of the situation in postmenopausal women 
receiving HRT (Odum et al., 1997). Treatment with E2 resulted in an increase of the 
uterus wet weights, whereas nutrition exerts no effects (Tab. 6). In a previous 
experiment of our laboratory, an additional increase in the uterine wet weights could 
be observed in animals which received lifelong an ISO-rich or GEN-rich diet 
compared to an IDD group (Moller et al., 2010). The ISD of the present study 
contained 2-times lower concentrations of ISO as the ISO-rich diet, indicating a 
dose-response effect of ISO on uterine wet weights. Additionally, a lower E2 
concentration was chosen in the present study, as it has been shown that E2 
concentrations at doses between 1 and 10 µg/kg BW (s. c.) exert physiological 
effects on the rat uterus (Odum et al., 1997). 
Analysis of the proliferation marker Ki-67 and PCNA on mRNA level revealed that 
the E2-induced proliferation was reduced after pre-exposure to ISO (Fig. 15 A/B). 
This observation indicates that exposure to ISO starting prepubertal is sufficient to 
reduce the estrogen induced proliferative response of the mammary gland. 
Numerous studies described that ISO exert protective effects on the mammary 
gland if the exposure starts prepubertal (Wu et al., 1996; Shu et al., 2001; 
Lamartiniere, 2002; Wu et al., 2002). This could be explained by the fact that GEN is 
able to alter the morphology of the mammary gland if the ingestion starts before 
pubertal breast development occurs. It has for example already been shown that 
prepubertal exposure to GEN increases the differentiation of the mammary gland by 
leading to an increase in the number of differentiated lobules and a reduction in the 
number of terminal end buds. The increased differentiation of the mammary gland 
results in a reduced risk to develop cancer in this tissue (Cotroneo et al., 2002; 
Lamartiniere, 2002; Cabanes et al., 2004). 
In contrast to proliferation, PR expression was induced in IDD as well as in pISD 
animals, suggesting an increased estrogen sensitivity in animals which received ISO 
only pre- to postpuberty (Fig. 15 C). This is in line with the observations in the PND 
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50 and 80 animals, which also showed an increased PR expression after pre- to 
postpubertal ISO exposure (Fig. 14 C). In addition to the earlier onset of puberty and 
the shorter menstrual cycle length, ISO exposure starting shortly before the onset of 
puberty seems to increase the estrogen sensitivity of the mammary gland. This led 
to the hypothesis that the imprinting of the estrogen sensitivity occurs at an earlier 
stage of life, before PND 30. As proliferation of the mammary gland is reduced after 
pre- to postpubertal ISO exposure, it could be assumed that the proliferative 
response of the mammary gland is formed at a later developmental stage, during 
PND 30 and 60. In line with other studies, it could be hypothesized that the reduced 
proliferative response to estrogens results from an altered pubertal breast 
development after ISO exposure. Our assumption is confirmed by a study of Clarke 
who showed that proliferating cells rarely express the PR, indicating that there are 
two distinct populations in normal mammary glands (Clarke et al., 1997).  
As reported before, numerous studies suggested a protective role of ISO exposure 
towards the development of breast cancer, if the ingestion starts prepubertal, 
because of the ability of ISO to alter the morphology of the mammary gland during 
pubertal breast growth (Limer & Speirs, 2004; Warri et al., 2008; Messina & Hilakivi-
Clarke, 2009). Further studies revealed that ISO are also able to induce epigenetic 
changes (Guerrero-Bosagna et al., 2008; Li et al., 2009; Molinie & Georgel, 2009). 
The group of Dolinoy showed that in utero exposure to Bisphenol A (50 mg/kg diet) 
resulted in epigenetic abnormalities, which could be reversed through maternal 
dietary supplementation with GEN (250 mg/kg diet) (Dolinoy et al., 2007). There is 
evidence that the early post-conceptional period displays a critical window, as it 
could be shown that in mammals the genomic methylation profile is reprogrammed 
during gametogenesis and in early embryogenesis (Barker, 2004; Gluckman et al., 
2007; Reik, 2007). This lead to the assumption that the increased estrogen 
sensitivity in the pISD compared to the ISD group could be due to epigenetic 
changes in the ISD which are mediated by early life ISO exposure.  
In summary, our results provide evidence that the imprinting of the estrogen 
sensitivity occurs in an earlier stage of life than the imprinting of the proliferative 
response of the mammary gland towards estrogens. In the present study, the 
estrogen induced proliferation was reduced due to ISO exposure solely during PND 
30 and 60, while this timeframe seems too late to influence estrogen sensitivity. 
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CHAPTER FIVE 
General discussion 
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Differences in the incidence of hormone dependent cancer between Eastern Asia 
and Europe or the US have been described many years ago (Ursin et al., 1994; 
Adlercreutz & Mazur, 1997; Martinez, 2005). Studies indicate that the traditional 
East Asian diet which is rich in soy may be responsible for cancer preventive effects.  
Aim of the present thesis was to analyse whether dietary exposure to ISO during 
different windows of development alters the estrogen susceptibility of the mammary 
gland and the tissue homeostasis of the small intestine in female rats. 
The first question addressed was whether lifelong exposure to dietary soy ISO or 
lifelong exposure solely to GEN influences the sensitivity of the mammary gland 
towards estradiol (E2). In the corresponding experiment three different kinds of diets 
were chosen: an ISO-free diet (IDD), an ISO-rich diet (IRD) and a GEN-rich diet 
(GRD). The IDD can be compared to the European nutrition containing less than 1 
mg ISO per day, resulting in plasma concentrations of 10 nM ISO (Adlercreutz et al., 
1993). The IRD reflects the Eastern Asian diet traditionally being rich in soy (20–50 
mg ISO/day), and resulting in a total serum ISO level (sum of GEN, DAI and equol) 
of 0.87 µM (Adlercreutz, 2002). The IRD used in the present study contained 248 µg 
GEN/ g, 213 µg DAI/g and 59 µg GLY/g diet (each calculated as aglycones). This 
results in an average daily ISO intake of 33 mg/kg BW of an adult female rat and 
ISO serum concentrations of 1.1 µM GEN and 2 µM DAI. Compared to the human 
situation, this concentration of the IRD is relatively high. 
During the last years the range of soy supplement products increases, although the 
effects of isolated intake of ISO are uncertain. In the present study, the GRD should, 
in regards to the daily ISO intake and the ISO plasma level, reflect the consumption 
of relatively high amounts of solely GEN (700 µg/g diet) in the form of soy 
supplements. It is described that consumption of soy supplements results in an 
average ISO intake of 20–80 mg/day, and plasma ISO levels of 1–3 µM are 
achieved (Gardner et al., 2009). Given the chosen diet, the adult female rats 
consuming the GRD accordingly reached a daily intake of 42 mg GEN/kg BW, 
resulting in serum concentrations of 2.5 µM.  
The results have shown that mammary gland proliferation was increased after IRD 
and GRD on PND 50. This suggests that puberty was still ongoing, and goes along 
with the assumption of an improved breast development after lifelong ISO exposure 
(Fritz et al., 1998). As expected, no proliferation could be detected at PND 80. Both 
results show that the points of time were appropriate to analyse the influence of ISO 
on the mammary gland in regards to the investigated hypothesis. 
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After ovariectomie and treatment with E2, the protective effects of ISO exposure 
became even more apparent. Lifelong exposure to IRD or GRD resulted in a 
reduced sensitivity of the mammary gland towards estrogens which was indicated 
by reduced expressions of PCNA and PR, increased expressions of PS2 and a 
decrease in the ratio of ERα:ERβ compared to IDD fed animals. The fact that an 
expected increase of proliferation could be detected after treatment with E2 
confirmed the general effectiveness of the treatment and thus the assay setup to 
analyse estrogenic effects in the mammary gland. 
Comparison of the results of the IRD and GRD groups revealed that both diets led to 
a similar reduction of estrogen sensitivity, whereas the IRD seemed more effective, 
although it contains less ISO than the GRD (IRD: sum of GEN, DAI, and GLY: 520 
µg/g diet; GRD: 700 µg GEN/g diet). This can be explained by the fact that the IRD 
included the ISO DAI, which is converted to equol in rodents. Equol has more 
estrogenic potency than GEN and DAI, and could therefore be responsible for the 
stronger effects of the IRD (Lamartiniere et al., 2002b; Rafii et al., 2007). Taken 
together, lifelong consumption of a diet containing the whole spectrum of soy ISO 
results in a further reduction of the mammary gland sensitivity than a diet containing 
high amounts of solely GEN.  
The second question addressed the effects of an IRD or GRD on the small intestine 
of female rats. The experiment utilized the same animals as from the first part of the 
thesis. In contrast to mammary gland, which is only rudimentary present before 
onset of puberty, the small intestine was additionally analysed on PND 25. In the 
small intestine, the elevated expression of PS2 and PCNA indicates an increased 
resistance of intestinal damage, in line with the hypothesis that loss of PS2 seems 
as an early indicator in developing intestinal cancer (Wu et al., 1998).  
The E2 treatment led to reduced expressions of p63 and PS2 and a tendency of 
reduced proliferation in the present experiment. As p63 and PS2 expressions were 
lowest after lifelong exposure to IRD or GRD it can be taken as an indication of 
improved intestinal protection. The fact that only a tendency of reduced proliferation 
was shown can be explained by the treatment period of three days which is very 
short for non-classical estrogen tissues like the small intestine. Previous 
experiments by other groups with long-term treatment with E2 have shown stronger 
protective effects (Chlebowski et al., 2004; Wada-Hiraike et al., 2006). 
Overall, lifelong dietary exposure to ISO may improve not only the development of 
the mammary gland but also the small intestine of female rats. Thus, these 
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observations as well confirmed the hypothesis that lifelong exposure to ISO and 
solely GEN protects against hormone-dependent cancers such as breast or bowel 
cancer. 
The third and final question addressed aimed to analyse whether not lifelong but 
only pre- to postpubertal exposure to ISO is sufficient to reduce the sensitivity of the 
mammary gland towards E2. For a better comparability of the diets, the IRD was 
replaced by an ISO-containing diet (ISD), which had the same composition as the 
IDD, but included soy ISO. The ISD contained less ISO than the IRD (ISD: 147.41 
µg GEN/g diet, 113.54 µg DAI/g diet, 36.06 µg GLY/g diet; IRD: 247.59 µg GEN/g 
diet, 213.09 µg DAI/g diet, 58.89 µg GLY/g diet, each calculated as aglycones). This 
results in a daily ISO consumption for an adult female rat of 33 mg/kg BW (for IRD) 
respectively of 19 mg/kg BW (for ISD). Given the high turn-over rate in rats 
compared to humans, a daily ISO intake of 17 mg/kg BW of rodents is comparable 
with an average ISO intake of 2.5 mg/kg BW in Eastern Asian populations, thus 
having the ISD appropriately reflecting the ISO intake of Asians. 
For the induction of estrogen-dependent proliferation in the mammary gland, an E2 
dose of 4 µg/kg BW was chosen. While this is a lower dose than in the first breeding 
experiment (7.8 µg/kg BW), it falls into the range between 1 and 10 µg/kg BW which 
exerts physiological estrogenic effects in the rat uterus (Odum et al., 1997). Both 
estrogen concentrations resulted in a significant increase of estrogen-induced 
proliferation in the mammary gland. 
The results of this breeding experiment revealed that pre- to postpubertal exposure 
to dietary ISO results in an earlier onset of puberty and a shorter menstrual cycle. 
Furthermore, these animals showed an increased PR expression in the mammary 
gland at PND 50 and 80. In response to treatment with E2 the PR expression was 
highest in pISD compared to IDD and ISD while the proliferation was reduced. This 
firstly suggests that pre- to postpubertal exposure is not effectual in reducing the 
estrogen sensitivity of the mammary gland. Secondly it could be assumed that the 
imprinting of estrogen sensitivity and proliferative response of the mammary gland 
occurs not contemporaneous but at different developmental stages. 
In summary, the results from both experiments provide evidence that lifelong 
exposure to dietary ISO cause reduced estrogen sensitivity and proliferative 
response of the mammary gland, which may lead to a reduced breast cancer risk. 
This reduction is more significant after the intake of the full spectrum of soy ISO than 
after GEN alone. Furthermore, the estrogen sensitivity of the mammary gland 
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seems to be formed at an earlier developmental stage compared to the estrogen-
dependent proliferation. Additionally, the tissue homeostasis of the small intestine 
was improved in the animals of the first breeding experiment, indicating a protection 
from developing cancer in the intestine.  
Given the indication from the present thesis that lifelong exposure to dietary ISO 
reduces the estrogen sensitivity of the mammary gland of female rats, whereas pre- 
to postpubertal exposure did not, future experiments may analyse different windows 
of development to more precisely define the time frame of protective ISO exposure. 
Future research should as well take into consideration which setup – animal or 
human studies – can achieve best results given the limitations of the circumstances. 
Extrapolations from in vivo studies to the human situation are quite difficult and 
should only be made cautiously. For example, this study used a conversation factor 
to improve comparability as the metabolism of nutrients occurs faster in rats than in 
humans (Setchell et al., 2011). Going further, some studies indicated that equol 
contributes to the protective effects of ISO, and while rats are able to convert DAI to 
the more estrogenic metabolit equol, this ability exerts on only 30–50 % of the 
human population.(Shor et al., 2012). Furthermore, nutritional composition differs 
between rats and humans, which may influence the metabolism of ISO. For 
example, it has been suggested that high intake of dietary fat impairs the production 
of ISO metabolites (Rowland et al., 2000).  
On the other hand, in human studies, it is not possible to include or even to 
determine and control all variables having an impact on the study readout, such as 
nutrition or life habits, making it difficult to compare the study subjects with each 
other. Furthermore, because of differences between the individuals, a large number 
of study subjects are needed to give evidence. Taken together, both study designs 
have advantages and disadvantages, resulting in the conclusion that a combination 
could be the method of choice. 
The present thesis investigated the impact of ISO on the most common cancers in 
females: breast and bowel cancer. Looking further, the question arises about the 
impact of ISO exposure on cancers in men. Most frequently in men are prostate and 
bowel cancer and differences in the incidence of bowel cancer in men and women 
have been discussed (Jimenez et al., 2011). The risk for bowel cancer seems to be 
dependent on the estrogen level as shown in studies where postmenopausal 
women receiving a hormone replacement therapy (HRT) have a lower cancer risk 
than women receiving no HRT (reviewed in (Di Leo et al., 2001; Nelson et al., 2002; 
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Kennelly et al., 2008)). Yet, the influence of ISO on bowel cancer in men is 
discussed controversial. The Fukuoka Colorectal Cancer Study showed an inverse 
relationship between nutritional intake of ISO and colorectal cancer risk in men and 
postmenopausal women, but not in premenopausal women (Budhathoki et al., 
2011). In contrast, a meta-analysis revealed that soy intake was associated with a 
reduction of colon cancer risk in women, but not in men (Yan et al., 2010). 
Furthermore, the incidence of prostate cancer is much lower for men from Eastern 
Asia compared to European men (Adlercreutz, 1995; Fritz et al., 2002; Kurahashi et 
al., 2007), and a lot of animal models showed a reduction in prostate cancer in 
response to GEN (Mentor-Marcel et al., 2001; Lamartiniere et al., 2002a; Wang et 
al., 2002). The underlying mechanisms are still unclear, but it has been described 
that GEN is able to improve prostate differentiation which may lead to reduced 
cancer development (Fritz et al., 2002). A further study showed a reduction in the 
weight of prostate and seminal vesicle after oral treatment with GEN (100 mg/kg 
BW) for 14 days. Additionally, in this study beneficial effect of GEN treatment in a 
model of chronic colitis could be observed (Seibel et al., 2009).  
The controversial discussion shows that while the results from this study strengthen 
the hypothesis on ISO impact for females, it cannot be easily transferred to men. 
Further studies are needed to identify the impact of ISO exposure on men.  
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